US20030065379A1 - Reduction of stent thrombogenicity - Google Patents

Reduction of stent thrombogenicity Download PDF

Info

Publication number
US20030065379A1
US20030065379A1 US10/287,416 US28741602A US2003065379A1 US 20030065379 A1 US20030065379 A1 US 20030065379A1 US 28741602 A US28741602 A US 28741602A US 2003065379 A1 US2003065379 A1 US 2003065379A1
Authority
US
United States
Prior art keywords
submucosal tissue
stent
tissue
luminal
submucosal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/287,416
Inventor
Charles Babbs
Neal Fearnot
Stephen Badylak
Leslie Geddes
Michael Hiles
Joe Bourland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/429,308 external-priority patent/US5693085A/en
Application filed by Individual filed Critical Individual
Priority to US10/287,416 priority Critical patent/US20030065379A1/en
Publication of US20030065379A1 publication Critical patent/US20030065379A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/04Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06Blood vessels
    • A61F2/07Stent-grafts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/95Instruments specially adapted for placement or removal of stents or stent-grafts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/95Instruments specially adapted for placement or removal of stents or stent-grafts
    • A61F2/958Inflatable balloons for placing stents or stent-grafts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/005Ingredients of undetermined constitution or reaction products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08Materials for coatings
    • A61L31/10Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/18Use of ingredients of undetermined constitution or reaction products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M29/00Dilators with or without means for introducing media, e.g. remedies
    • A61M29/02Dilators made of swellable material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/88Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure the wire-like elements formed as helical or spiral coils
    • A61F2/885Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure the wire-like elements formed as helical or spiral coils comprising a coil including a plurality of spiral or helical sections with alternate directions around a central axis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/04Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06Blood vessels
    • A61F2/07Stent-grafts
    • A61F2002/072Encapsulated stents, e.g. wire or whole stent embedded in lining
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/04Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06Blood vessels
    • A61F2/07Stent-grafts
    • A61F2002/075Stent-grafts the stent being loosely attached to the graft material, e.g. by stitching
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/95Instruments specially adapted for placement or removal of stents or stent-grafts
    • A61F2/958Inflatable balloons for placing stents or stent-grafts
    • A61F2002/9583Means for holding the stent on the balloon, e.g. using protrusions, adhesives or an outer sleeve
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2220/00Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2220/0008Fixation appliances for connecting prostheses to the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2220/00Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2220/0025Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements
    • A61F2220/005Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements using adhesives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2220/00Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2220/0025Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements
    • A61F2220/0075Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements sutured, ligatured or stitched, retained or tied with a rope, string, thread, wire or cable
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2240/00Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2240/001Designing or manufacturing processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067Means for introducing or releasing pharmaceutical products into the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/0043Catheters; Hollow probes characterised by structural features
    • A61M25/0045Catheters; Hollow probes characterised by structural features multi-layered, e.g. coated

Definitions

  • This invention relates to an intestinal tissue covered prosthesis useful in promoting the resurfacing and repair of damaged or diseased tissue structures. More particularly this invention is directed to stents having a layer of submucosal tissue covering a surface of the stent, and their use in repairing damaged or diseased physiological vessels, particularly blood vessels.
  • Atherosclerosis in which cholesterol and fibrous tissue, often together with calcium precipitates, gradually build up within the inner layers of the arterial wall, diminishing the cross sectional area available for blood flow.
  • Thrombosis can produce sudden cessation of blood flow with disastrous consequences for downstream organs such as the brain, heart muscle, kidney, or lower extremities.
  • the eroded, abnormal intimal surface of sclerotic vessels causes additional complications including fragmentation of atherosclerotic material with downstream embolization and hemorrhage or dissection of blood into the plaque itself causing sudden expansion of the lesion and occlusion of the vessel.
  • PTA Percutaneous transluminal angioplasty
  • a balloon catheter has an expandable sac that can be expanded and contracted in a controlled manner in response to inflation pressure.
  • Balloon catheter angioplasty involves positioning the balloon catheter at a stenotic site and inflating the sac to a predetermined size to open the stenotic or occluded portion of the blood vessel. The sac is then deflated and the catheter removed leaving a larger lumen.
  • Standard balloon angioplasty with or without the use of stents, produces a torn vessel with myointimal flaps and exposed fissures. These provide thrombogenic surfaces and sites for hemodynamic dissection.
  • Angioplasty is now known to damage the vessel wall by tearing and stretching, and this form of controlled injury opens the vessel lumen and increases blood flow acutely in nearly all cases.
  • abrupt vessel closure during or immediately following PTA and late restenosis continues to limit the effectiveness of the procedure.
  • catheters have been fitted with vascular stents.
  • Stents are three dimensional implantable structures that (upon delivery to an intra vessel position) physically hold a blood vessel open.
  • Vascular stents are typically formed to fit on the end of conventional catheters for delivery of the stent to a predetermined intravascular location.
  • a number of stents for coronary use are commercially available. They differ in physicochemical characteristics and the mode of implantation. Ideally, a stent should be flexible, thrombo-resistant, low in profile, radiopaque, limit the expansion of repair tissues into the lumen of the vessel, and have an easy, reliable delivery system.
  • Self-expanding stents utilize a spring mechanism to constrain the stent to a compressed shape. Upon removal of the constraint, the stent expands to a predetermined dimension.
  • Balloon expandable stents are expandable members formed to fit over a balloon catheter and capable of being expanded in response to controlled inflation of the balloon catheter. Inflation of the balloon results in plastic deformation of the stent beyond its elastic limits so that the stent remains in its expanded state upon subsequent deflation and removal of the balloon catheter.
  • stents used in conjunction with PTA are “expandable stents” having an initial collapsed state that allows the stent to be delivered to the desired intravascular location with minimal longitudinal shearing action. Upon delivery to the desired location the stent is expanded to fix the stent at that location and to physically hold the vessel open.
  • the present invention utilizes a natural collagenous matrix comprising submucosal tissue in combination with known angioplastic techniques to eliminate complications that derive from the residual abnormal, thrombogenic surfaces produced by current available angioplastic techniques such as ordinary balloon angioplasty, laser angioplasty, and transluminal mechanical arthrectomy.
  • the collagenous matrices for use in accordance with the present invention comprise highly conserved collagens, glycoproteins, proteoglycans, and glycosaminoglycans in their natural configuration and natural concentration.
  • On preferred collagenous matrix comprises warm-blooded vertebrate submucosa.
  • the submucosa is isolated from warm-blooded vertebrate tissues including the alimentary, respiratory, intestinal, urinary or genital tracts of warm-blooded vertebrates.
  • the preparation of intestinal submucosa is described and claimed in U.S. Pat. No. 4,902,508, the disclosure of which is expressly incorporated herein by reference.
  • Urinary bladder submucosa and its preparation is described in U.S. Pat. No. 5,554,389, the disclosure of which is expressly incorporated herein by reference.
  • Stomach submucosa has also been obtained and characterized using similar tissue processing techniques. Such is described in U.S. patent application No.
  • stomach submucosa is prepared from a segment of stomach in a procedure similar to the preparation of intestinal submucosa.
  • a segment of stomach tissue is first subjected to abrasion using a longitudinal wiping motion to remove the outer layers (particularly the smooth muscle layers) and the luminal portions of the tunica mucosa layers.
  • the resulting submucosa tissue has a thickness of about 100 to about 200 micrometers, and consists primarily (greater than 98%) of acellular, eosinophilic staining (H&E stain) extracellular matrix material.
  • H&E stain acellular, eosinophilic staining
  • Preferred submucosal tissues for use in accordance with this invention include intestinal submucosa, stomach submucosa, urinary bladder submucosa, and uterine submucosa.
  • Intestinal submucosal tissue is one preferred starting material, and more particularly intestinal submucosa delaminated from both the tunica muscularis and at least the tunica mucosa of warm-blooded vertebrate intestine.
  • tissue graft As a tissue graft, submucosal tissue undergoes remodeling and induces the growth of endogenous tissues upon implantation into a host. It has been used successfully in vascular grafts, urinary bladder and hernia repair, replacement and repair of tendons and ligaments, and dermal grafts. The preparation and use of submucosa as a tissue graft composition is described in U.S. Pat. Nos. 4,902,508; 5,281,422; 5,275,826; 5,554,389; and other related U.S. patents.
  • the graft constructs When used in such applications the graft constructs appear not only to serve as a matrix for the regrowth of the tissues replaced by the graft constructs, but also promote or induce such regrowth of endogenous tissue.
  • Common events to this remodeling process include: widespread and very rapid neovascularization, proliferation of granulation mesenchymal cells, biodegradation/resorption of implanted intestinal submucosal tissue material, and lack of immune rejection.
  • the use of submucosal tissue in sheet form and fluidized forms for inducing the formation of endogenous tissues is described and claimed in U.S. Pat. Nos. 5,281,422 and 5,275,826, the disclosures of which are expressly incorporated herein by reference.
  • the present invention is directed to an improved prosthetic device for repairing the intima surface of damaged or diseased vessels.
  • the prosthetic devices of the present invention can also be used in traditional PTA procedures to open narrowed or occluded vessels.
  • the prosthetic device comprises a cylindrical shaped expandable member having a luminal and exterior surface, and a layer of submucosal tissue fixed to the exterior or luminal surface of the member.
  • the expandable member is typically a stent wherein expansion of the stent increases the circumference of said member, thus fixing the device at a predetermined location within the vessel.
  • FIG. 1 is a cross-sectional view of a balloon catheter carrying a submucosa tissue coated stent in accordance with this invention.
  • FIG. 2 is a sectional view of a submucosa covered stent positioned on a mandrel.
  • FIG. 3 a - 3 c are perspective views of a stent, wrapped longitudinally with one or more sheets of submucosal tissue.
  • FIG. 3 a illustrates a stent, wrapped longitudinally with a single sheet of submucosal tissue.
  • FIG. 3 c and FIG. 3 d illustrate a stent wrapped with three separate sheets of submucosal tissue, each sheet forming a single loop of submucosal tissue, wherein the stent is shown in its condensed state (FIG. 3 c ) or in its expanded state (FIG. 3 d ).
  • FIG. 4 a and 4 b are perspective views of a tube of submucosa having a plurality of longitudinal slits formed in the walls of the tube.
  • FIG. 4 a shows the tissue in its compact state
  • FIG. 4 b shows the tissue in its expanded state.
  • FIG. 5 a - 5 d illustrates the construction of one embodiment of a submucosa covered stent.
  • FIG. 6 a illustrates a stent wire covered with a narrow sheet of submucosal tissue
  • FIG. 6 b and FIG. 6 c illustrate a stent formed from the submucosa tissue covered wire of FIG. 6 a.
  • FIG. 7 illustrates an alternative embodiment of a submucosa covered wire for forming stents in accordance with this invention.
  • the present invention is directed to an improved vascular stent composition and a method for repairing the inner linings of damaged or diseased vessels.
  • the method comprises the step of applying a new, non-thrombogenic intimal surface of submucosal tissue over the former damaged or diseased intima.
  • the term “vessel” as used herein is defined as including any bodily canal, conduit, duct or passageway, including but not limited to blood vessels, bile ducts, the esophagus, the trachea, the ureter and the urethra.
  • the vessel is expanded to increase the lumen of the vessel simultaneously with the application of a layer of submucosal tissue. Applicants have discovered that the applied submucosal tissue layer provides a non-thrombogenic surface that induces the formation of a new endothelium and inhibits restenosis of a vessel after expansion of the vessel.
  • Submucosal tissue suitable for use in the present invention comprises naturally associated extracellular matrix proteins, glycoproteins, proteoglycans, glycosaminoglycans and other factors in their natural configuration and natural concentration.
  • Submucosal tissue can be prepared from a variety of natural sources including the alimentary, respiratory, intestinal, urinary or genital tracts of warm-blooded vertebrates.
  • the submucosal tissue comprises intestinal submucosa delaminated from both the tunica muscularis and at least the luminal portion of the tunica mucosa.
  • the intestinal submucosal tissue comprises the tunica submucosa and basilar portions of the tunica mucosa including the lamina muscularis mucosa and the stratum compactum which layers are known to vary in thickness and in definition dependent on the source vertebrate species.
  • intestinal submucosal tissue for use in accordance with this invention is described in U.S. Pat. No. 4,902,508.
  • a segment of vertebrate intestine preferably harvested from porcine, ovine or bovine species, but not excluding other species, is subjected to abrasion using a longitudinal wiping motion to remove the outer layers, comprising smooth muscle tissues, and the innermost layer, i.e., the luminal portion of the tunica mucosa.
  • One preferred source of intestinal submucosa is the small intestine of mature adult pigs weighing greater than 450 lbs.
  • the submucosal tissue is rinsed several times with saline and optionally sterilized.
  • the submucosal tissue of the present invention can be sterilized using conventional sterilization techniques including glutaraldehyde tanning, formaldehyde tanning at acidic pH, propylene oxide treatment, gas plasma sterilization, gamma radiation, electron beam radiation, and peracetic acid sterilization. Sterilization techniques which do not adversely affect the mechanical strength, structure, and biotropic properties of the submucosal tissue is preferred. For instance, strong gamma radiation may cause loss of strength of the sheets of submucosal tissue.
  • Preferred sterilization techniques include exposing the graft to peracetic acid, 1-4 Mrads gamma irradiation (more preferably 1-2.5 Mrads of gamma irradiation) or gas plasma sterilization; peracetic acid sterilization is the most preferred sterilization method.
  • Submucosal tissue treated with peracetic acid exhibits little if any significant post-implantation calcification.
  • the treatment is typically conducted at a pH of about 2 to about 5 in an aqueous ethanolic solution (about 2 to about 10% ethanol by volume) at a peracid concentration of about 0.03 to about 0.5% by volume.
  • the submucosal tissue is subjected to two or more sterilization processes. After the submucosal tissue is sterilized, for example by chemical treatment, the tissue may be wrapped in a plastic or foil wrap and sterilized again using electron beam or gamma irradiation sterilization techniques.
  • the submucosal tissue specified for use in accordance with this invention can also be in a fluidized form.
  • the preparation of fluidized forms of submucosa tissue is described in U.S. Pat. No. 5,275,826, the disclosure of which is expressly incorporated herein by reference.
  • Fluidized forms of submucosal tissue are prepared by comminuting submucosa tissue by tearing, cutting, grinding, or shearing the harvested submucosal tissue.
  • pieces of submucosal tissue can be comminuted by shearing in a high speed blender, or by grinding the submucosa in a frozen or freeze-dried state to produce a powder that can thereafter be hydrated with water or a buffered saline to form a submucosal fluid of liquid, gel or paste-like consistency.
  • the comminuted submucosa formulation can further be treated with an enzymatic composition to provide a homogenous solution of partially solubilized submucosa.
  • the enzymatic composition may comprise one or more enzymes that are capable of breaking the covalent bonds of the structural components of the submucosal tissue.
  • the comminuted submucosal tissue can be treated with a collagenase, glycosaminoglycanase, or a protease, such as trypsin or pepsin at an acidic pH, for a period of time sufficient to solubilize all or a major portion of the submucosal tissue protein components.
  • the tissue is optionally filtered to provide a homogenous solution.
  • the viscosity of fluidized submucosa for use in accordance with this invention can be manipulated by controlling the concentration of the submucosa component and the degree of hydration.
  • the viscosity can be adjusted to a range of about 2 to about 300,000 cps at 25° C.
  • Higher viscosity formulations, for example, gels, can be prepared from the submucosa digest solutions by adjusting the pH of such solutions to about 6.0 to about 7.0.
  • Submucosal tissue can be stored in a hydrated or dehydrated state. Lyophilized or air dried submucosa tissue can be rehydrated and used in accordance with this invention without significant loss of its biotropic and mechanical properties.
  • Submucosal tissue can be used in accordance with the present invention in combination with standard PTA devices to form prosthetic devices suitable for use in PTA procedures.
  • the method of repairing vessels in vivo through the use of the disclosed devices comprises the steps of contacting the intima surface of the vessel with submucosal tissue and holding the submucosal tissue in place to provide a new intima surface.
  • the implanted layer of submucosal tissue induces the growth of new endothelium without stenosis, and therefore the submucosal tissue is preferably held in contact with the site in need of repair for a time sufficient to induce the formation of a new intima surface.
  • the tissue graft construct is permanently located within a blood vessel or other structure and is ultimately replaced by endogenous cell growth.
  • submucosal tissue is used in combination with known angioplastic techniques and devices to provide an improved composition and method for repairing damaged or diseased portions of vessels.
  • the improvement method comprises fixing a graft construct comprising submucosal tissue onto the surface of a catheter and delivering the tissue graft construct to a predetermined intra-vessel location. It is anticipated that the vessel walls of any bodily vessel, conduit, canal or body cavity that is accessible to a catheter, can be repaired using the method described in the present invention.
  • the catheter can be used to position the submucosal graft constructs to an intra-vessel location for contact with a diseased or damaged surface of the vessel.
  • the catheter is a balloon catheter, and the balloon portion is covered with submucosal tissue.
  • inflation of the balloon presses the submucosal tissue against the intima surface of the vessel.
  • deflation of the balloon portion allows the removal of the catheter, leaving the submucosal tissue positioned in contact with the intima surface of the vessel.
  • the submucosal tissue is preferably combined with additional elements to enhance the retention of the submucosal tissue layer on the original intima surface including, use of anchoring projections (such as plastic or metal pins), adhesives, stents, or other fixation devices known to those skilled in the art.
  • anchoring projections such as plastic or metal pins
  • adhesives such as plastic or metal pins
  • stents or other fixation devices known to those skilled in the art.
  • the submucosal tissue is held in contact with the intima surface through the use of a stent.
  • an improved stent for opening obstructed or occluded vessicles.
  • the improved stent comprises a conventional expandable stent, wherein the exterior surface of the stent is covered with submucosal tissue.
  • the submucosal tissue covers the original intima surface of the vessel to provide a smooth, non-thrombogenic surface.
  • the exterior surface of a stent is covered with submucosal tissue and a catheter is used to position the stent to a predetermined location in a blood vessel.
  • the stent is expanded, and thereby expands the lumen of the vessel, and the submucosal tissue is pressed against the luminal surface of the vessel thus covering the arteriosclerotic lesions and the surface of blood vessels damaged through the angioplasty procedure.
  • Table 1 provides a list of several stents suitable for use in accordance with the present invention, however the list is not exhaustive and additional stents known to those skilled in the art can be used in accordance with the present invention.
  • TABLE 1 Design and Characteristics of Stents in Clinical Evaluation Filament Filament Stent Stent Surface Stent Configuration Composition Thickness (mm) Diameter (mm) Length (mm) Area (%) Radiopaque Self-expanding Wallset Wire-mesh Stainless 0.07-0.10 3.5-6.0 21-45 18.5-20 No Steel Balloon- expandable Palmaz- Slotted tube Stainless 0.08 3.0-4.0 15 10 No Schatz Steel Gianturco- Incomplete Stainless 0.15 2.0-4.0 20 10 No Roubin coil Steel Wiktok Helical coil Tantalum 0.125 3.0-4.0 15-17 5-10 Yes Streker Woven wire Stainless 0.07 2.0-3.5 15-25 — No steel/ Yes tantalum
  • a prosthetic device utilizing a stent incorporates a conventional balloon angioplasty catheter around which are placed, in order, an expandable vascular stent, and a layer of submucosal tissue.
  • the stent can be sandwiched between two layers of submucosal tissue (i.e., one layer covering the luminal surface of the stent and one layer covering the external surface of the stent).
  • the submucosal tissue is immobilized onto the stent through the use of adhesives, sutures, interweaving the tissue with the stent struts or other fixation techniques known to those skilled in the art.
  • the graft constructs of the present invention can be utilized in combination with conventional prosthetic devices known to those skilled in the art as being useful for vessel repair.
  • the submucosal tissue constructs of the present invention are fixed onto the distal end of a prosthetic device, such as a catheter, using a variety of techniques including: frictional engagement, applying the tissue onto the surface of the prosthetic device followed by drying the material, suturing the tissue to the device, and other means known to those skilled in the art.
  • the graft construct comprises an expandable cylindrical shaped member that has submucosal tissue covering at least the external surface of the member.
  • the lumen of the cylindrical member is sized for receiving the distal end of a catheter, and more preferably the expandable member is formed to frictionally engage the exterior surface of the distal end of the catheter. The expansion of the expandable member increases the circumference of the cylindrical shaped member thus fixing the submucosal tissue against the luminal surface of the vessel and allowing for the removal of the catheter after deployment of the graft construct.
  • the catheter comprises a balloon-type catheter and the expandable member comprises a stent that is expanded to a fixed enlarged size by the inflation of the balloon catheter.
  • inflation of the submucosal tissue/stent-covered balloon catheter accomplishes several therapeutic objectives, almost simultaneously.
  • the stent in combination with intra-arterial pressure, holds the submucosal tissue against the intima surface of the vessel covering any cracks, fissures, or tears in the vessel that result during balloon inflation.
  • Such defects in blood vessels are highly thrombogenic when exposed to the blood stream.
  • the new submucosal tissue also provides a barrier between the metallic stent and vascular smooth muscle, inhibiting late re-stenosis.
  • the submucosal tissue layer covers the old, diseased inner lining of the vessel (tunica intima), substituting a smooth, non-thrombogenic surface, into which healthy new endothelial cells can grow, ultimately replacing the submucosal tissue with new endothelium.
  • stents that are best suited for use in accordance with the present invention are metallic (typically stainless steel or tantalum) and are carried in a collapsed form over a conventional balloon angioplasty catheter. When the balloon is inflated the stent is deployed and expanded to its working, in vivo size.
  • stents such as self-expanding stents, can also be used in accordance with the present invention to resurface damaged or diseased body vessels.
  • One submucosal tissue covered stent construct suitable for use in the present invention comprises a stent having one or more pieces of submucosal covering the exposed external surfaces of the stent.
  • the stent Upon implantation into a host the submucosal tissue is held between the stent and the diseased vessel wall.
  • the stent is positioned to the desired location in the vessel through the use of a balloon-type catheter.
  • a single lumen angioplasty catheter 1 having an inflatable balloon 2 , which is semi-rigid or rigid upon inflation, carries a vascular stent 3 covered with small intestinal submucosa 4 .
  • This embodiment of the invention is intended for segments of vessels without significant side branches, such as the renal arteries, the common carotid arteries, or the popliteal arteries. Because of the absence of significant side branches, the lack of perforations in the submucosal tissue will not pose problems for tissue perfusion.
  • the submucosal tissue 12 overlays both the luminal surface 18 and the exterior surface 20 of the stent 10 to covered all stent surfaces with submucosal tissue 12 .
  • a submucosal tissue covered stent is prepared in accordance with one embodiment by first preparing a tubular submucosal tissue construct, longer than the stent (preferably twice as long as the stent).
  • a mandrel 26 of the appropriate size is inserted into the lumen of a tube of submucosal tissue and the stent 10 is then fashioned around the submucosal tissue 12 .
  • a lumen 28 is formed between the outer and inner layers of the submucosal tissue.
  • the lumen 28 can optionally be filled with fluidized submucosal tissue, growth factors, a heparin containing composition or other components to assist the repair of the damaged or diseased vessel.
  • the tube of submucosal tissue used to prepare the submucosa covered stents of the present invention can be prepared in accordance with procedures described in U.S. Pat. No. 5,902,508.
  • a tube of submucosa tissue is prepared from intestinal submucosa that has been delaminated from both the tunica muscularis and at lest the luminal portion of the tunica mucosa.
  • the appropriate sized lumen of the tube of submucosa can be prepared by inserting a glass rod/mandrel, having the appropriate diameter, into the lumen of the tube of submucosa and gathering up the redundant tissue and suturing longitudinally along the gathered material.
  • a sheet of submucosa can be used to form the tube of submucosal tissue.
  • the sheet of submucosal tissue is rolled up around the distal end of the catheter and the opposing lateral ends are situated to form a tube that frictionally engages the catheter.
  • the graft construct can be formed to define a tube of submucosa having a diameter approximately the same as the catheter by wrapping the submucosal tissue around an appropriately sized mandrel. The formed tube of submucosal tissue can then be fixed onto the distal end of a catheter.
  • the tube of submucosal tissue is held in its cylindrical shape by sutures, adhesives, compressing the tissue under dehydration conditions, heat treating the tissue, the use of crosslinking agents or any combination thereof.
  • multiple strips of submucosal tissue are overlapped with one another as they are wrapped onto the mandrel to form a multi-layered tube of submucosal tissue.
  • the submucosal tissue can be wrapped onto the mandrel in a variety of different orientations, provided that no gaps exist between the seams of overlapped tissue that would expose the surface of the mandrel.
  • a submucosal tissue covered stent construct is formed by wrapping the stent with one or more strips of submucosal to cover both the luminal and the exterior surfaces of the stent.
  • a single long narrow sheet of submucosal tissue 36 can be wrapped longitudinally along the exterior surface of the stent 38 starting at one end of the stent, running along the exterior surface to the second end of the stent and then running along the luminal surface, from the second end back to the first end (See FIG. 3 a ).
  • the longitudinal wrapping is continued forming continuous loops of submucosal tissue that cover the luminal and exterior surfaces of the stent 38 .
  • the strip of submucosal tissue is wrapped longitudinally so that each loop overlaps with the previously underlying strip.
  • the overlapped region may range from about 20% up to about 75%.
  • the width of the individual strips and the amount of overlap will vary according to the size and type of stent selected.
  • the stent can optionally be covered with additional strips of submucosal tissue to increase the thickness of the submucosal layer.
  • the appropriate parameters width of the sheet of submucosal tissue and percent overlap
  • the individual loops of overlapped submucosal tissue will slide over one another to allow for the increased size of the stent without exposing the surface of the stent
  • the luminal and exterior surfaces are covered by a single strip of submucosal tissue, wherein the strip of submucosal tissue has a width less than the circumference of the stent.
  • the strip of submucosal tissue is longitudinally wrapped about the exterior and luminal surfaces to form loops of submucosal tissue that cover the entire surface of the stent.
  • the loops of submucosal tissue will overlap with each other to such an extent that the stent can be expanded to its in vivo working size without exposing the surface of the stent.
  • both the luminal surface an the exterior surface of the stent are covered by a plurality of separate sheets of submucosal tissue, each of which are wrapped longitudinally about the exterior and luminal surface of the stent to form loops of submucosal tissue.
  • three sheets of submucosal tissue each having a first end 70 and a second end 72 are longitudinally wrapped around the luminal and exterior surface of the stent and the first and second ends ( 70 and 72 , respectively) are sutured together to form 3 separate loops of submucosal tissue.
  • the stent has a collapsed luminal diameter CD and the three sheets of submucosal tissue overlap one another by an overlap region, OR 1 .
  • the diameter of the stent lumen is expanded to a second diameter, ED, wherein ED is greater than CD.
  • ED is greater than CD.
  • the sheets of submucosa slide past one another to account for the increase in the circumference of the expanded stent and the overlapped region decreases in size to a distance OR 2 wherein OR 1 , is greater than OR 2 .
  • the individual loops of submucosal tissue shown in FIG. 3 c and FIG. 3 d cover only the exterior surface of the stent, and the two opposite ends of each sheet of submucosal tissue are looped around the first and second end coil, respectively, of the stent and sutured.
  • FIG. 4 a and 4 b a sleeve of submucosal tissue 30 is placed over a stent, and the tissue covered stent is placed over an angioplasty balloon. Staggered rows of longitudinal slits 32 are cut in the submucosal tissue, as shown in FIG. 4 a .
  • the balloon-stent unit When the balloon-stent unit is expanded, the submucosal tissue opens to form a submucosal tissue mesh 34 , through which blood can pass from the central lumen into side branches (FIG. 4 b ).
  • the mesh provides a matrix for in growth of native endothelial tissue, however high blood flow rates through the open spaces in the mesh where vessel side branches exist will tend to retard thrombosis, maintaining the opening in the submucosal mesh. Occasional obstruction of a side branch by the substance of the mesh can occur, but by optimizing mesh size, blood flow to the side branches will be preserved.
  • Attachment of the slit submucosal tissue to the coils of the underlying stent is accomplished by the placement of sutures through adjacent slits in the tissue and around individual stent coils to form gathers of submucosal tissue.
  • the meshwork opens to the pre-planned final diameter, and the gathers are drawn taut.
  • a slitted tube of submucosal tissue can be used to cover both the exterior and luminal surface of the stent to repair vessels that have several branches.
  • a slitted sheet of tubular submucosal tissue, twice as long as the stent, is laid down over the surface of a mandrel, and a stent is fashioned around it. Then the leading and trailing edges of slitted submucosal tissue are everted, brought back over the exterior surface of the stent and sutured together to secure the submucosal tissue around both the blood-facing and tissue-facing surfaces of the stent.
  • the single suture line is sufficient to secure the submucosal tissue in place.
  • the stent can be fixed onto the distal end of a balloon type catheter and when the balloon stent complex is expanded in vivo, the meshwork opens to allow blood to pass from the central lumen into side branches.
  • submucosal tissue-covered stent corrects two resultant abnormalities of atherosclerotic occlusive disease in one simple mechanical treatment.
  • First angioplasty with stent placement reverses the chronic stenosis caused by atherosclerotic plaque material.
  • submucosal tissue can be dried, stored, and rehydrated without loss of mechanical strength or thromboresistance.
  • submucosal tissue can be applied to angioplasty catheters, and stored in conventional sterile packages., and rehydrated at the time of use by immersion in sterile saline.
  • a segment of intestinal tissue (the proximal jejunum) from the donor species of choice is collected within 1 to 3 hours of death.
  • the submucosal tissue prepared as described in U.S. Pat. No. 4,902,508, is sized to make the diameter of the implant less than or equal to the normal caliber of expected recipient blood vessel (i.e., isodiametric).
  • a sterile glass rod having the same diameter as that of the target vessel is selected and placed into the graft lumen. This reduced diameter allows for the initial 10 to 20% dilation that occurs after exposure to the systemic circulation and eventual isodiametric size.
  • Redundant tissue is then gathered and the desired lumen diameter achieved by using either two continuous suture lines or a simple interrupted suture line with 5-0 polypropylene suture material with a swaged, tapercut needle.
  • the material is then fixed onto the pre-made stent-and-balloon catheter and the cut longitudinal ends are tucked under the ends of the stent or otherwise secured to the stent, for example by suturing the submucosa to the individual coils of the stent (See FIG. 1).
  • the preferred stent design is one that does not change length during deployment, and thus does not create longitudinal folds or wrinkles in the submucosal tissue.
  • Submucosal tissue can be fixed onto a stent by interweaving the submucosal tissue onto the individual coils of a wire stent as shown in FIG. 5 a .
  • First the stent 43 is made from a single wire 44 that is bent back and forth to form a coil, as shown in FIG. 5 a
  • a sheet of dry submucosal tissue sheet 42 is then interweaved with the zig-zag shaped stent wires as shown in FIG. 5 a .
  • a first end of the submucosal tissue 46 is sutured to one end of the stent wires 46 , whereas the opposite free end 48 extends beyond the unsutured end of the stent wires as shown in FIGS.
  • FIG. 5 b is an exploded view illustrating the interweaving of the coiled stent with the submucosal tissue.
  • FIG. 5 c illustrates the complete construct and
  • FIG. 5 d provides a sectional view of the submucosal tissue covered stent. Note that the opposite free end 48 extends beyond the coils of the stent 40 so that when the stent is expanded in the blood vessel, there is enough submucosal tissue to fully cover the stent.
  • FIG. 5 b shows how the stent wires interweave.
  • the submucosal tissue is fixed to the stent by spiral wrapping sheets of submucosal tissue on a stent wire (See FIG. 6 a ), then forming the stent, as shown in FIG. 6 b and 6 c .
  • the stent is made by starting with a straight stent wire 50 which is covered with submucosal tissue.
  • the wire is covered with two or more strands of dry submucosal tissue 52 by braiding as shown in FIG. 6 a .
  • the submucosal tissue is wetted and allowed to dry. Therefore the strands of submucosal tissue form a braided sleeve that covers the wire.
  • the stent wire can be coated with a fluidized form of submucosal tissue and allowed to dry.
  • the wire is bent into a stent as shown in FIGS. 6 b and 6 c.
  • the submucosal tissue can also be fixed onto the stent wire without first cutting a prepared tube of submucosa into narrow sheets of submucosa.
  • the stent wire 62 is passed through the lumen of the prepared tube of submucosal tissue 60 (FIG.7).
  • the tube of submucosal tissue 60 will then be stretched by pulling the two ends away from each other, to decrease the diameter of the prepared tube of submucosal tissue, thereby forming a closely fitting covering for the stent wire, as shown in FIG. 7.
  • the gut-covered stent wire is then coiled as in FIG. 6 b to form the expandable stent.
  • the submucosal tissue is positioned within the luminal space of a stent so the two ends of the submucosal tissue extend past the ends of the stent. The two ends of the submucosal tissue will then be everted and pulled back over the exterior portion of the stent and sutured at the midline of the stent. Thus both the exterior and luminal surface of the stent will be covered with the submucosal tissue.
  • This submucosal tissue covered stent is then deployed in the bile duct of the dogs using the following procedure which entails a laparotomy in the dog under general anesthesia.
  • a midline incision from umbilicus to xiphisternum will be performed with dissection to and opening of the peritoneum performed in accordance with procedures known to those skilled in the art.
  • the common bile duct will be identified and followed to the duodenum.
  • a duodenotomy will be performed and the major papilla identified.
  • a 24 cm submucosal tissue coated 11.5 Fr biliary stent will be placed into the common bile duct with the distal portion of the stent protruding through the papilla and draining into the duodenum.
  • the duodenotomy and abdominal wall incisions will be closed and the animal allowed to recover from anesthesia in an intensive care cage.
  • the dogs will be monitored by the Medical Research Lab Animal Technicians and be allowed food and water approximately 24 hours post-operatively. Post-operative analgesia (torbutrol) will be administered as required.

Abstract

A tissue graft construct and method for repairing the inner linings of damaged or diseased vertebrate vessels is described. The method comprises the steps of positioning a tissue graft construct within a blood vessel at a site in need of repair. The tissue graft construct comprises a stent (3) covered with submucosal tissue (4) wherein the stent (3) is formed for receiving the distal end of a catheter (1) having an inflatable balloon (2).

Description

    FIELD OF THE INVENTION
  • This invention relates to an intestinal tissue covered prosthesis useful in promoting the resurfacing and repair of damaged or diseased tissue structures. More particularly this invention is directed to stents having a layer of submucosal tissue covering a surface of the stent, and their use in repairing damaged or diseased physiological vessels, particularly blood vessels. [0001]
  • BACKGROUND AND SUMMARY OF THE INVENTION
  • The most common cause of vascular disease in the Western world is atherosclerosis, in which cholesterol and fibrous tissue, often together with calcium precipitates, gradually build up within the inner layers of the arterial wall, diminishing the cross sectional area available for blood flow. There are two essential abnormalities of such atherosclerotic lesions that cause complications. The first is the narrowing of the lumen, which produces a chronic limitation of blood flow distally. The second is the abnormally raised, roughened inner surface of the artery, the physical properties of which tend to induce platelet adhesion and clot formation at the diseased site. Thrombosis can produce sudden cessation of blood flow with disastrous consequences for downstream organs such as the brain, heart muscle, kidney, or lower extremities. The eroded, abnormal intimal surface of sclerotic vessels causes additional complications including fragmentation of atherosclerotic material with downstream embolization and hemorrhage or dissection of blood into the plaque itself causing sudden expansion of the lesion and occlusion of the vessel. [0002]
  • Percutaneous transluminal angioplasty (PTA), first performed 25 years ago by Dotter and Judkins, is the technique of opening narrowed or occluded blood vessels by passing guide wires and catheters through the stenotic or occluded portion of the blood vessel. Dotter's original PTA method involved inserting increasingly larger catheters over a guidewire to progressively dilate the vessel. Later modifications utilized graduated catheters with gradually tapering tips, which created more lateral compression and less longitudinal shearing action. These early PTA procedures were limited by the requisite stiffness of the catheters and by the large puncture wounds required for the procedure. [0003]
  • In 1974, PTA procedures were revolutionized by the introduction of balloon catheter angioplasty. A balloon catheter has an expandable sac that can be expanded and contracted in a controlled manner in response to inflation pressure. Balloon catheter angioplasty involves positioning the balloon catheter at a stenotic site and inflating the sac to a predetermined size to open the stenotic or occluded portion of the blood vessel. The sac is then deflated and the catheter removed leaving a larger lumen. Standard balloon angioplasty, with or without the use of stents, produces a torn vessel with myointimal flaps and exposed fissures. These provide thrombogenic surfaces and sites for hemodynamic dissection. Furthermore, although the use of the stents in PTA procedures gives highly predictable immediate angiographic results, those stents all suffer the disadvantage that they have limited long term efficacy. Despite holding the vessel open, the natural reparative processes at a stent-dilated vessel result in healing tissues growing around the stent structure and eventually occluding the lumen of the vessel. In addition to PTA procedures, alternative techniques for removing atherosclerotic plaques include laser angioplasty and mechanical arthrectomy devices, which can vaporize, melt, or remove plaque material. However all such systems leave an abnormal, thrombogenic surface. [0004]
  • Angioplasty is now known to damage the vessel wall by tearing and stretching, and this form of controlled injury opens the vessel lumen and increases blood flow acutely in nearly all cases. However, abrupt vessel closure during or immediately following PTA and late restenosis continues to limit the effectiveness of the procedure. To enhance the efficacy of PTA procedures catheters have been fitted with vascular stents. [0005]
  • Stents are three dimensional implantable structures that (upon delivery to an intra vessel position) physically hold a blood vessel open. Vascular stents are typically formed to fit on the end of conventional catheters for delivery of the stent to a predetermined intravascular location. A number of stents for coronary use are commercially available. They differ in physicochemical characteristics and the mode of implantation. Ideally, a stent should be flexible, thrombo-resistant, low in profile, radiopaque, limit the expansion of repair tissues into the lumen of the vessel, and have an easy, reliable delivery system. Currently available expandable stents can be categorized as “self expandable stents” and “balloon expandable stents.” Self-expanding stents utilize a spring mechanism to constrain the stent to a compressed shape. Upon removal of the constraint, the stent expands to a predetermined dimension. Balloon expandable stents are expandable members formed to fit over a balloon catheter and capable of being expanded in response to controlled inflation of the balloon catheter. Inflation of the balloon results in plastic deformation of the stent beyond its elastic limits so that the stent remains in its expanded state upon subsequent deflation and removal of the balloon catheter. Preferably stents used in conjunction with PTA are “expandable stents” having an initial collapsed state that allows the stent to be delivered to the desired intravascular location with minimal longitudinal shearing action. Upon delivery to the desired location the stent is expanded to fix the stent at that location and to physically hold the vessel open. [0006]
  • The present invention utilizes a natural collagenous matrix comprising submucosal tissue in combination with known angioplastic techniques to eliminate complications that derive from the residual abnormal, thrombogenic surfaces produced by current available angioplastic techniques such as ordinary balloon angioplasty, laser angioplasty, and transluminal mechanical arthrectomy. The collagenous matrices for use in accordance with the present invention comprise highly conserved collagens, glycoproteins, proteoglycans, and glycosaminoglycans in their natural configuration and natural concentration. On preferred collagenous matrix comprises warm-blooded vertebrate submucosa. [0007]
  • In accordance with the present invention the submucosa is isolated from warm-blooded vertebrate tissues including the alimentary, respiratory, intestinal, urinary or genital tracts of warm-blooded vertebrates. The preparation of intestinal submucosa is described and claimed in U.S. Pat. No. 4,902,508, the disclosure of which is expressly incorporated herein by reference. Urinary bladder submucosa and its preparation is described in U.S. Pat. No. 5,554,389, the disclosure of which is expressly incorporated herein by reference. Stomach submucosa has also been obtained and characterized using similar tissue processing techniques. Such is described in U.S. patent application No. 60/032,683 titled STOMACH SUBMUCOSA DERIVED TISSUE GRAFT, filed on Dec. 10, 1996. Briefly, stomach submucosa is prepared from a segment of stomach in a procedure similar to the preparation of intestinal submucosa. A segment of stomach tissue is first subjected to abrasion using a longitudinal wiping motion to remove the outer layers (particularly the smooth muscle layers) and the luminal portions of the tunica mucosa layers. The resulting submucosa tissue has a thickness of about 100 to about 200 micrometers, and consists primarily (greater than 98%) of acellular, eosinophilic staining (H&E stain) extracellular matrix material. [0008]
  • Preferred submucosal tissues for use in accordance with this invention include intestinal submucosa, stomach submucosa, urinary bladder submucosa, and uterine submucosa. Intestinal submucosal tissue is one preferred starting material, and more particularly intestinal submucosa delaminated from both the tunica muscularis and at least the tunica mucosa of warm-blooded vertebrate intestine. [0009]
  • As a tissue graft, submucosal tissue undergoes remodeling and induces the growth of endogenous tissues upon implantation into a host. It has been used successfully in vascular grafts, urinary bladder and hernia repair, replacement and repair of tendons and ligaments, and dermal grafts. The preparation and use of submucosa as a tissue graft composition is described in U.S. Pat. Nos. 4,902,508; 5,281,422; 5,275,826; 5,554,389; and other related U.S. patents. When used in such applications the graft constructs appear not only to serve as a matrix for the regrowth of the tissues replaced by the graft constructs, but also promote or induce such regrowth of endogenous tissue. Common events to this remodeling process include: widespread and very rapid neovascularization, proliferation of granulation mesenchymal cells, biodegradation/resorption of implanted intestinal submucosal tissue material, and lack of immune rejection. The use of submucosal tissue in sheet form and fluidized forms for inducing the formation of endogenous tissues is described and claimed in U.S. Pat. Nos. 5,281,422 and 5,275,826, the disclosures of which are expressly incorporated herein by reference. [0010]
  • The present invention is directed to an improved prosthetic device for repairing the intima surface of damaged or diseased vessels. The prosthetic devices of the present invention can also be used in traditional PTA procedures to open narrowed or occluded vessels. In one embodiment the prosthetic device comprises a cylindrical shaped expandable member having a luminal and exterior surface, and a layer of submucosal tissue fixed to the exterior or luminal surface of the member. The expandable member is typically a stent wherein expansion of the stent increases the circumference of said member, thus fixing the device at a predetermined location within the vessel.[0011]
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a cross-sectional view of a balloon catheter carrying a submucosa tissue coated stent in accordance with this invention. [0012]
  • FIG. 2 is a sectional view of a submucosa covered stent positioned on a mandrel. [0013]
  • FIG. 3[0014] a-3 c are perspective views of a stent, wrapped longitudinally with one or more sheets of submucosal tissue. FIG. 3a illustrates a stent, wrapped longitudinally with a single sheet of submucosal tissue. FIG. 3c and FIG. 3d illustrate a stent wrapped with three separate sheets of submucosal tissue, each sheet forming a single loop of submucosal tissue, wherein the stent is shown in its condensed state (FIG. 3c) or in its expanded state (FIG. 3d).
  • FIG. 4[0015] a and 4 b are perspective views of a tube of submucosa having a plurality of longitudinal slits formed in the walls of the tube. FIG. 4a shows the tissue in its compact state and FIG. 4b shows the tissue in its expanded state.
  • FIG. 5[0016] a-5 d illustrates the construction of one embodiment of a submucosa covered stent.
  • FIG. 6[0017] a illustrates a stent wire covered with a narrow sheet of submucosal tissue and FIG. 6b and FIG. 6c illustrate a stent formed from the submucosa tissue covered wire of FIG. 6a.
  • FIG. 7 illustrates an alternative embodiment of a submucosa covered wire for forming stents in accordance with this invention.[0018]
  • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention is directed to an improved vascular stent composition and a method for repairing the inner linings of damaged or diseased vessels. The method comprises the step of applying a new, non-thrombogenic intimal surface of submucosal tissue over the former damaged or diseased intima. The term “vessel” as used herein is defined as including any bodily canal, conduit, duct or passageway, including but not limited to blood vessels, bile ducts, the esophagus, the trachea, the ureter and the urethra. In one embodiment the vessel is expanded to increase the lumen of the vessel simultaneously with the application of a layer of submucosal tissue. Applicants have discovered that the applied submucosal tissue layer provides a non-thrombogenic surface that induces the formation of a new endothelium and inhibits restenosis of a vessel after expansion of the vessel. [0019]
  • Submucosal tissue suitable for use in the present invention comprises naturally associated extracellular matrix proteins, glycoproteins, proteoglycans, glycosaminoglycans and other factors in their natural configuration and natural concentration. Submucosal tissue can be prepared from a variety of natural sources including the alimentary, respiratory, intestinal, urinary or genital tracts of warm-blooded vertebrates. [0020]
  • In one embodiment of the present invention the submucosal tissue comprises intestinal submucosa delaminated from both the tunica muscularis and at least the luminal portion of the tunica mucosa. In another embodiment the intestinal submucosal tissue comprises the tunica submucosa and basilar portions of the tunica mucosa including the lamina muscularis mucosa and the stratum compactum which layers are known to vary in thickness and in definition dependent on the source vertebrate species. [0021]
  • The preparation of intestinal submucosal tissue for use in accordance with this invention is described in U.S. Pat. No. 4,902,508. A segment of vertebrate intestine, preferably harvested from porcine, ovine or bovine species, but not excluding other species, is subjected to abrasion using a longitudinal wiping motion to remove the outer layers, comprising smooth muscle tissues, and the innermost layer, i.e., the luminal portion of the tunica mucosa. One preferred source of intestinal submucosa is the small intestine of mature adult pigs weighing greater than 450 lbs. The submucosal tissue is rinsed several times with saline and optionally sterilized. [0022]
  • The submucosal tissue of the present invention can be sterilized using conventional sterilization techniques including glutaraldehyde tanning, formaldehyde tanning at acidic pH, propylene oxide treatment, gas plasma sterilization, gamma radiation, electron beam radiation, and peracetic acid sterilization. Sterilization techniques which do not adversely affect the mechanical strength, structure, and biotropic properties of the submucosal tissue is preferred. For instance, strong gamma radiation may cause loss of strength of the sheets of submucosal tissue. Preferred sterilization techniques include exposing the graft to peracetic acid, 1-4 Mrads gamma irradiation (more preferably 1-2.5 Mrads of gamma irradiation) or gas plasma sterilization; peracetic acid sterilization is the most preferred sterilization method. [0023]
  • Submucosal tissue treated with peracetic acid exhibits little if any significant post-implantation calcification. The treatment is typically conducted at a pH of about 2 to about 5 in an aqueous ethanolic solution (about 2 to about 10% ethanol by volume) at a peracid concentration of about 0.03 to about 0.5% by volume. Typically, the submucosal tissue is subjected to two or more sterilization processes. After the submucosal tissue is sterilized, for example by chemical treatment, the tissue may be wrapped in a plastic or foil wrap and sterilized again using electron beam or gamma irradiation sterilization techniques. [0024]
  • The submucosal tissue specified for use in accordance with this invention can also be in a fluidized form. The preparation of fluidized forms of submucosa tissue is described in U.S. Pat. No. 5,275,826, the disclosure of which is expressly incorporated herein by reference. Fluidized forms of submucosal tissue are prepared by comminuting submucosa tissue by tearing, cutting, grinding, or shearing the harvested submucosal tissue. Thus pieces of submucosal tissue can be comminuted by shearing in a high speed blender, or by grinding the submucosa in a frozen or freeze-dried state to produce a powder that can thereafter be hydrated with water or a buffered saline to form a submucosal fluid of liquid, gel or paste-like consistency. [0025]
  • The comminuted submucosa formulation can further be treated with an enzymatic composition to provide a homogenous solution of partially solubilized submucosa. The enzymatic composition may comprise one or more enzymes that are capable of breaking the covalent bonds of the structural components of the submucosal tissue. For example, the comminuted submucosal tissue can be treated with a collagenase, glycosaminoglycanase, or a protease, such as trypsin or pepsin at an acidic pH, for a period of time sufficient to solubilize all or a major portion of the submucosal tissue protein components. After treating the comminuted submucosa formulation with the enzymatic composition, the tissue is optionally filtered to provide a homogenous solution. [0026]
  • The viscosity of fluidized submucosa for use in accordance with this invention can be manipulated by controlling the concentration of the submucosa component and the degree of hydration. The viscosity can be adjusted to a range of about 2 to about 300,000 cps at 25° C. Higher viscosity formulations, for example, gels, can be prepared from the submucosa digest solutions by adjusting the pH of such solutions to about 6.0 to about 7.0. [0027]
  • Submucosal tissue can be stored in a hydrated or dehydrated state. Lyophilized or air dried submucosa tissue can be rehydrated and used in accordance with this invention without significant loss of its biotropic and mechanical properties. [0028]
  • Submucosal tissue can be used in accordance with the present invention in combination with standard PTA devices to form prosthetic devices suitable for use in PTA procedures. Applicants anticipate that the use of the present tissue graft constructs comprising submucosal tissue will enhance the repair of damaged or diseased vessels and thus improve the effectiveness of PTA procedures. The method of repairing vessels in vivo through the use of the disclosed devices comprises the steps of contacting the intima surface of the vessel with submucosal tissue and holding the submucosal tissue in place to provide a new intima surface. Advantageously, the implanted layer of submucosal tissue induces the growth of new endothelium without stenosis, and therefore the submucosal tissue is preferably held in contact with the site in need of repair for a time sufficient to induce the formation of a new intima surface. In preferred embodiments the tissue graft construct is permanently located within a blood vessel or other structure and is ultimately replaced by endogenous cell growth. [0029]
  • In one embodiment of the present invention submucosal tissue is used in combination with known angioplastic techniques and devices to provide an improved composition and method for repairing damaged or diseased portions of vessels. The improvement method comprises fixing a graft construct comprising submucosal tissue onto the surface of a catheter and delivering the tissue graft construct to a predetermined intra-vessel location. It is anticipated that the vessel walls of any bodily vessel, conduit, canal or body cavity that is accessible to a catheter, can be repaired using the method described in the present invention. [0030]
  • Conventional catheters can be used to position the submucosal graft constructs to an intra-vessel location for contact with a diseased or damaged surface of the vessel. In accordance with one embodiment, the catheter is a balloon catheter, and the balloon portion is covered with submucosal tissue. Upon positioning of the submucosal tissue covered catheter within a vessel, inflation of the balloon presses the submucosal tissue against the intima surface of the vessel. Subsequent deflation of the balloon portion allows the removal of the catheter, leaving the submucosal tissue positioned in contact with the intima surface of the vessel. [0031]
  • The submucosal tissue is preferably combined with additional elements to enhance the retention of the submucosal tissue layer on the original intima surface including, use of anchoring projections (such as plastic or metal pins), adhesives, stents, or other fixation devices known to those skilled in the art. In preferred embodiments the submucosal tissue is held in contact with the intima surface through the use of a stent. [0032]
  • In accordance with one embodiment an improved stent is provided for opening obstructed or occluded vessicles. The improved stent comprises a conventional expandable stent, wherein the exterior surface of the stent is covered with submucosal tissue. Upon deployment of the submucosal tissue covered stent, the submucosal tissue covers the original intima surface of the vessel to provide a smooth, non-thrombogenic surface. For example, in one embodiment the exterior surface of a stent is covered with submucosal tissue and a catheter is used to position the stent to a predetermined location in a blood vessel. The stent is expanded, and thereby expands the lumen of the vessel, and the submucosal tissue is pressed against the luminal surface of the vessel thus covering the arteriosclerotic lesions and the surface of blood vessels damaged through the angioplasty procedure. [0033]
  • Table 1 provides a list of several stents suitable for use in accordance with the present invention, however the list is not exhaustive and additional stents known to those skilled in the art can be used in accordance with the present invention. [0034]
    TABLE 1
    Design and Characteristics of Stents in Clinical Evaluation
    Filament Filament Stent Stent Surface
    Stent Configuration Composition Thickness (mm) Diameter (mm) Length (mm) Area (%) Radiopaque
    Self-expanding
    Wallset Wire-mesh Stainless 0.07-0.10 3.5-6.0 21-45 18.5-20   No
    Steel
    Balloon-
    expandable
    Palmaz- Slotted tube Stainless 0.08 3.0-4.0 15 10 No
    Schatz Steel
    Gianturco- Incomplete Stainless 0.15 2.0-4.0 20 10 No
    Roubin coil Steel
    Wiktok Helical coil Tantalum  0.125 3.0-4.0 15-17  5-10 Yes
    Streker Woven wire Stainless 0.07 2.0-3.5 15-25 No
    steel/ Yes
    tantalum
  • In one embodiment, a prosthetic device utilizing a stent incorporates a conventional balloon angioplasty catheter around which are placed, in order, an expandable vascular stent, and a layer of submucosal tissue. Alternatively the stent can be sandwiched between two layers of submucosal tissue (i.e., one layer covering the luminal surface of the stent and one layer covering the external surface of the stent). The submucosal tissue is immobilized onto the stent through the use of adhesives, sutures, interweaving the tissue with the stent struts or other fixation techniques known to those skilled in the art. [0035]
  • The graft constructs of the present invention can be utilized in combination with conventional prosthetic devices known to those skilled in the art as being useful for vessel repair. For example the submucosal tissue constructs of the present invention are fixed onto the distal end of a prosthetic device, such as a catheter, using a variety of techniques including: frictional engagement, applying the tissue onto the surface of the prosthetic device followed by drying the material, suturing the tissue to the device, and other means known to those skilled in the art. [0036]
  • In one preferred embodiment, the graft construct comprises an expandable cylindrical shaped member that has submucosal tissue covering at least the external surface of the member. In this embodiment the lumen of the cylindrical member is sized for receiving the distal end of a catheter, and more preferably the expandable member is formed to frictionally engage the exterior surface of the distal end of the catheter. The expansion of the expandable member increases the circumference of the cylindrical shaped member thus fixing the submucosal tissue against the luminal surface of the vessel and allowing for the removal of the catheter after deployment of the graft construct. [0037]
  • In one embodiment the catheter comprises a balloon-type catheter and the expandable member comprises a stent that is expanded to a fixed enlarged size by the inflation of the balloon catheter. In this embodiment, inflation of the submucosal tissue/stent-covered balloon catheter accomplishes several therapeutic objectives, almost simultaneously. First, as in conventional balloon angioplasty, the lumen is forcibly dilated to reverse narrowing caused by an atherosclerotic plaque. Second, the vascular stent maintains the expanded caliber of the vessel, providing a degree of rigid support and maintaining a circular, isodiametric cross-sectional profile. In addition the stent, in combination with intra-arterial pressure, holds the submucosal tissue against the intima surface of the vessel covering any cracks, fissures, or tears in the vessel that result during balloon inflation. Such defects in blood vessels are highly thrombogenic when exposed to the blood stream. The new submucosal tissue also provides a barrier between the metallic stent and vascular smooth muscle, inhibiting late re-stenosis. Finally, the submucosal tissue layer covers the old, diseased inner lining of the vessel (tunica intima), substituting a smooth, non-thrombogenic surface, into which healthy new endothelial cells can grow, ultimately replacing the submucosal tissue with new endothelium. [0038]
  • Commercially available stents that are best suited for use in accordance with the present invention are metallic (typically stainless steel or tantalum) and are carried in a collapsed form over a conventional balloon angioplasty catheter. When the balloon is inflated the stent is deployed and expanded to its working, in vivo size. However, other types of stents, such as self-expanding stents, can also be used in accordance with the present invention to resurface damaged or diseased body vessels. [0039]
  • One submucosal tissue covered stent construct suitable for use in the present invention comprises a stent having one or more pieces of submucosal covering the exposed external surfaces of the stent. Upon implantation into a host the submucosal tissue is held between the stent and the diseased vessel wall. In one preferred embodiment the stent is positioned to the desired location in the vessel through the use of a balloon-type catheter. In this embodiment shown in FIG. 1, a single [0040] lumen angioplasty catheter 1 having an inflatable balloon 2, which is semi-rigid or rigid upon inflation, carries a vascular stent 3 covered with small intestinal submucosa 4. This embodiment of the invention is intended for segments of vessels without significant side branches, such as the renal arteries, the common carotid arteries, or the popliteal arteries. Because of the absence of significant side branches, the lack of perforations in the submucosal tissue will not pose problems for tissue perfusion.
  • In another embodiment (FIG. 2) the [0041] submucosal tissue 12 overlays both the luminal surface 18 and the exterior surface 20 of the stent 10 to covered all stent surfaces with submucosal tissue 12. Such a submucosal tissue covered stent is prepared in accordance with one embodiment by first preparing a tubular submucosal tissue construct, longer than the stent (preferably twice as long as the stent). A mandrel 26 of the appropriate size is inserted into the lumen of a tube of submucosal tissue and the stent 10 is then fashioned around the submucosal tissue 12. The leading edge 14 and trailing edge 16 of submucosal tissue 12 are inverted, brought back over the exterior surface 20 of the stent 10 and sutured together, as shown in cross-section in FIG. 2. In this embodiment, wherein both the luminal inward and exterior 20 surfaces of the stent are covered with submucosal tissue, a lumen 28 is formed between the outer and inner layers of the submucosal tissue. The lumen 28 can optionally be filled with fluidized submucosal tissue, growth factors, a heparin containing composition or other components to assist the repair of the damaged or diseased vessel.
  • The tube of submucosal tissue used to prepare the submucosa covered stents of the present invention can be prepared in accordance with procedures described in U.S. Pat. No. 5,902,508. In one embodiment a tube of submucosa tissue is prepared from intestinal submucosa that has been delaminated from both the tunica muscularis and at lest the luminal portion of the tunica mucosa. The appropriate sized lumen of the tube of submucosa can be prepared by inserting a glass rod/mandrel, having the appropriate diameter, into the lumen of the tube of submucosa and gathering up the redundant tissue and suturing longitudinally along the gathered material. [0042]
  • Alternatively, a sheet of submucosa can be used to form the tube of submucosal tissue. In one embodiment the sheet of submucosal tissue is rolled up around the distal end of the catheter and the opposing lateral ends are situated to form a tube that frictionally engages the catheter. Alternatively the graft construct can be formed to define a tube of submucosa having a diameter approximately the same as the catheter by wrapping the submucosal tissue around an appropriately sized mandrel. The formed tube of submucosal tissue can then be fixed onto the distal end of a catheter. The tube of submucosal tissue is held in its cylindrical shape by sutures, adhesives, compressing the tissue under dehydration conditions, heat treating the tissue, the use of crosslinking agents or any combination thereof. In one embodiment multiple strips of submucosal tissue are overlapped with one another as they are wrapped onto the mandrel to form a multi-layered tube of submucosal tissue. In accordance with the present invention the submucosal tissue can be wrapped onto the mandrel in a variety of different orientations, provided that no gaps exist between the seams of overlapped tissue that would expose the surface of the mandrel. [0043]
  • In one embodiment a submucosal tissue covered stent construct is formed by wrapping the stent with one or more strips of submucosal to cover both the luminal and the exterior surfaces of the stent. For example, a single long narrow sheet of [0044] submucosal tissue 36 can be wrapped longitudinally along the exterior surface of the stent 38 starting at one end of the stent, running along the exterior surface to the second end of the stent and then running along the luminal surface, from the second end back to the first end (See FIG. 3a). The longitudinal wrapping is continued forming continuous loops of submucosal tissue that cover the luminal and exterior surfaces of the stent 38. In one preferred embodiment the strip of submucosal tissue is wrapped longitudinally so that each loop overlaps with the previously underlying strip. The overlapped region may range from about 20% up to about 75%. The width of the individual strips and the amount of overlap will vary according to the size and type of stent selected. In addition, the stent can optionally be covered with additional strips of submucosal tissue to increase the thickness of the submucosal layer. The appropriate parameters (width of the sheet of submucosal tissue and percent overlap) will be selected to ensure that upon deployment of the stent 38 the stent surface will not become exposed. Accordingly, upon expansion of the circumference of the stent the individual loops of overlapped submucosal tissue will slide over one another to allow for the increased size of the stent without exposing the surface of the stent
  • In one embodiment the luminal and exterior surfaces are covered by a single strip of submucosal tissue, wherein the strip of submucosal tissue has a width less than the circumference of the stent. The strip of submucosal tissue is longitudinally wrapped about the exterior and luminal surfaces to form loops of submucosal tissue that cover the entire surface of the stent. Preferably the loops of submucosal tissue will overlap with each other to such an extent that the stent can be expanded to its in vivo working size without exposing the surface of the stent. [0045]
  • In another embodiment (FIG. 3[0046] b) both the luminal surface an the exterior surface of the stent are covered by a plurality of separate sheets of submucosal tissue, each of which are wrapped longitudinally about the exterior and luminal surface of the stent to form loops of submucosal tissue. As shown in FIG. 3b and 3 c three sheets of submucosal tissue each having a first end 70 and a second end 72 are longitudinally wrapped around the luminal and exterior surface of the stent and the first and second ends (70 and 72, respectively) are sutured together to form 3 separate loops of submucosal tissue. In the collapsed form shown in FIG. 3b the stent has a collapsed luminal diameter CD and the three sheets of submucosal tissue overlap one another by an overlap region, OR1. When the stent is deployed the diameter of the stent lumen is expanded to a second diameter, ED, wherein ED is greater than CD. (See FIG. 3c). The sheets of submucosa slide past one another to account for the increase in the circumference of the expanded stent and the overlapped region decreases in size to a distance OR2 wherein OR1, is greater than OR2. Hence, both the inward and outward facing surfaces of the stent remain covered with submucosal tissue, and both the blood and underlying vascular wall “see” only submucosal tissue. Alternatively in one embodiment the individual loops of submucosal tissue shown in FIG. 3c and FIG. 3d cover only the exterior surface of the stent, and the two opposite ends of each sheet of submucosal tissue are looped around the first and second end coil, respectively, of the stent and sutured.
  • Applications involving the repair of vessels that have several branches (such as the left anterior descending coronary artery, that has several smaller, but metabolically significant side branches) requires modification of the basic device. In accordance with FIG. 4[0047] a and 4 b, a sleeve of submucosal tissue 30 is placed over a stent, and the tissue covered stent is placed over an angioplasty balloon. Staggered rows of longitudinal slits 32 are cut in the submucosal tissue, as shown in FIG. 4a. When the balloon-stent unit is expanded, the submucosal tissue opens to form a submucosal tissue mesh 34, through which blood can pass from the central lumen into side branches (FIG. 4b).
  • The mesh provides a matrix for in growth of native endothelial tissue, however high blood flow rates through the open spaces in the mesh where vessel side branches exist will tend to retard thrombosis, maintaining the opening in the submucosal mesh. Occasional obstruction of a side branch by the substance of the mesh can occur, but by optimizing mesh size, blood flow to the side branches will be preserved. [0048]
  • Attachment of the slit submucosal tissue to the coils of the underlying stent is accomplished by the placement of sutures through adjacent slits in the tissue and around individual stent coils to form gathers of submucosal tissue. As the balloon stent complex is expanded in vivo, the meshwork opens to the pre-planned final diameter, and the gathers are drawn taut. [0049]
  • Alternatively, a slitted tube of submucosal tissue can be used to cover both the exterior and luminal surface of the stent to repair vessels that have several branches. In this embodiment, a slitted sheet of tubular submucosal tissue, twice as long as the stent, is laid down over the surface of a mandrel, and a stent is fashioned around it. Then the leading and trailing edges of slitted submucosal tissue are everted, brought back over the exterior surface of the stent and sutured together to secure the submucosal tissue around both the blood-facing and tissue-facing surfaces of the stent. In this case suturing the submucosal tissue to the individual coils of the stent is not necessary, the single suture line is sufficient to secure the submucosal tissue in place. The stent can be fixed onto the distal end of a balloon type catheter and when the balloon stent complex is expanded in vivo, the meshwork opens to allow blood to pass from the central lumen into side branches. [0050]
  • Deployment of a submucosal tissue-covered stent, corrects two resultant abnormalities of atherosclerotic occlusive disease in one simple mechanical treatment. First, angioplasty with stent placement reverses the chronic stenosis caused by atherosclerotic plaque material. Second, resurfacing with anchored submucosal tissue covers the old, complication prone, diseased surface with a smooth, fresh, biocompatible surface that is resistant to thrombosis, fragmentation, and dissection. Furthermore, submucosal tissue can be dried, stored, and rehydrated without loss of mechanical strength or thromboresistance. Thus submucosal tissue can be applied to angioplasty catheters, and stored in conventional sterile packages., and rehydrated at the time of use by immersion in sterile saline. [0051]
  • EXAMPLE 1 Preparation of a Submucosal Tissue Covered Stent
  • A segment of intestinal tissue (the proximal jejunum) from the donor species of choice is collected within 1 to 3 hours of death. The submucosal tissue, prepared as described in U.S. Pat. No. 4,902,508, is sized to make the diameter of the implant less than or equal to the normal caliber of expected recipient blood vessel (i.e., isodiametric). A sterile glass rod having the same diameter as that of the target vessel is selected and placed into the graft lumen. This reduced diameter allows for the initial 10 to 20% dilation that occurs after exposure to the systemic circulation and eventual isodiametric size. Redundant tissue is then gathered and the desired lumen diameter achieved by using either two continuous suture lines or a simple interrupted suture line with 5-0 polypropylene suture material with a swaged, tapercut needle. The material is then fixed onto the pre-made stent-and-balloon catheter and the cut longitudinal ends are tucked under the ends of the stent or otherwise secured to the stent, for example by suturing the submucosa to the individual coils of the stent (See FIG. 1). The preferred stent design is one that does not change length during deployment, and thus does not create longitudinal folds or wrinkles in the submucosal tissue. [0052]
  • EXAMPLE 2
  • Submucosal tissue can be fixed onto a stent by interweaving the submucosal tissue onto the individual coils of a wire stent as shown in FIG. 5[0053] a. First the stent 43 is made from a single wire 44 that is bent back and forth to form a coil, as shown in FIG. 5a A sheet of dry submucosal tissue sheet 42 is then interweaved with the zig-zag shaped stent wires as shown in FIG. 5a. A first end of the submucosal tissue 46 is sutured to one end of the stent wires 46, whereas the opposite free end 48 extends beyond the unsutured end of the stent wires as shown in FIGS. 5a and 5 c. Then the submucosal tissue-coated stent wires are bent into a cylindrical shape to form an incomplete tube, as shown in FIGS. 5b, 5 c and 5 d. FIG. 5b is an exploded view illustrating the interweaving of the coiled stent with the submucosal tissue. FIG. 5c illustrates the complete construct and FIG. 5d provides a sectional view of the submucosal tissue covered stent. Note that the opposite free end 48 extends beyond the coils of the stent 40 so that when the stent is expanded in the blood vessel, there is enough submucosal tissue to fully cover the stent. FIG. 5b shows how the stent wires interweave.
  • EXAMPLE 3
  • In an alternative embodiment the submucosal tissue is fixed to the stent by spiral wrapping sheets of submucosal tissue on a stent wire (See FIG. 6[0054] a), then forming the stent, as shown in FIG. 6b and 6 c. The stent is made by starting with a straight stent wire 50 which is covered with submucosal tissue. The wire is covered with two or more strands of dry submucosal tissue 52 by braiding as shown in FIG. 6a. When covered in this way, the submucosal tissue is wetted and allowed to dry. Therefore the strands of submucosal tissue form a braided sleeve that covers the wire. Alternatively the stent wire can be coated with a fluidized form of submucosal tissue and allowed to dry. The wire is bent into a stent as shown in FIGS. 6b and 6 c.
  • The submucosal tissue can also be fixed onto the stent wire without first cutting a prepared tube of submucosa into narrow sheets of submucosa. After preparing a tube of submucosal tissue as described in U.S. Pat. No. 4,902,508, the [0055] stent wire 62 is passed through the lumen of the prepared tube of submucosal tissue 60 (FIG.7). The tube of submucosal tissue 60 will then be stretched by pulling the two ends away from each other, to decrease the diameter of the prepared tube of submucosal tissue, thereby forming a closely fitting covering for the stent wire, as shown in FIG. 7. The gut-covered stent wire is then coiled as in FIG. 6b to form the expandable stent.
  • EXAMPLE 4 Implantation of Submucosa Covered Stents within Dogs
  • Five dogs (hounds, approximately 40 to 60 lbs) will undergo a laparotomy under general anesthesia (Pentothal I.V. and Isoflurane gas maintained at 2%) with placement of a 2-4 cm, small intestinal submucosa coated, 11.5 Fr. biliary stent. The stents will be Cotton Leung Biliary Stents manufactured by Wilson-Cook Medical, Inc. of Winston-Salem, N.C. Sterilized small submucosa is prepared in accordance with Example 1 in tubular form and having a length greater than the length of the stent. The submucosal tissue is positioned within the luminal space of a stent so the two ends of the submucosal tissue extend past the ends of the stent. The two ends of the submucosal tissue will then be everted and pulled back over the exterior portion of the stent and sutured at the midline of the stent. Thus both the exterior and luminal surface of the stent will be covered with the submucosal tissue. [0056]
  • This submucosal tissue covered stent is then deployed in the bile duct of the dogs using the following procedure which entails a laparotomy in the dog under general anesthesia. A midline incision from umbilicus to xiphisternum will be performed with dissection to and opening of the peritoneum performed in accordance with procedures known to those skilled in the art. The common bile duct will be identified and followed to the duodenum. A duodenotomy will be performed and the major papilla identified. After dilation of the papilla, a 24 cm submucosal tissue coated 11.5 Fr biliary stent will be placed into the common bile duct with the distal portion of the stent protruding through the papilla and draining into the duodenum. The duodenotomy and abdominal wall incisions will be closed and the animal allowed to recover from anesthesia in an intensive care cage. The dogs will be monitored by the Medical Research Lab Animal Technicians and be allowed food and water approximately 24 hours post-operatively. Post-operative analgesia (torbutrol) will be administered as required. [0057]
  • No drains will be placed in the animals and the post-operative recovery needs are expected to be those encountered with exploratory laparotomy alone. Animals will be observed for signs of sepsis, jaundice, bowel obstruction, etc. and euthanized at this time if necessary. Euthanasia will be by Socumb euthanasia solution, I.V., 1 ml/10 lbs. Dogs with uneventful post-operative courses will be euthanized at approximately 12 weeks; the biliary stent will be recovered at the time of postmortem examination of the abdomen with appropriate specimens of adjacent organs submitted for pathological examination. [0058]

Claims (20)

1. A prosthetic device for repairing the inner linings of damaged or diseased vertebrate vessels, said device comprising
a cylindrical shaped expandable member having a luminal and exterior surface, wherein expansion of said member increases the circumference of said member; and
a layer of submucosal tissue fixed to the luminal or exterior surface of said member.
2. The device of claim 1 wherein the cylindrical shaped member is a vascular stent having a lumen sized for receiving a catheter.
3. The device of claim 1 wherein the submucosal tissue comprises intestinal submucosa delaminated from both the tunica muscularis and at least the luminal portion of the tunica mucosa of a warm-blooded vertebrate.
4. The device of claim 3 wherein the submucosal tissue covers both the exterior and the luminal surface of the stent.
5. The device of claim 4, wherein said layer of submucosal tissue comprises a narrow sheet of submucosal tissue wrapped longitudinally about the luminal and exterior surface of the stent a plurality of times to form loops of submucosal tissue wherein each loop partially overlaps another loop of submucosal tissue.
6. The device of claim 4, wherein the layer of submucosal tissue comprises a plurality of narrow sheets of submucosal tissue having a first end and a second opposite end wrapped longitudinally about the luminal and exterior surface of the stent, wherein the first and second opposite ends of each sheet of submucosal tissue are bonded together to form loops of submucosal tissue and wherein each loop of submucosal tissue partially overlaps another loop of submucosal tissue.
7. The device of claim 2 wherein the means for expanding the stent comprises a releasable spring mechanism that biases the prosthetic device to a minimal circumference.
8. The device of claim 2 wherein the layer of submucosal tissue comprises fluidized submucosal tissue coated onto the surface of the stents.
9. The device of claim 2 wherein the submucosal tissue covering the stent is provided with a plurality of slits that upon expansion of the expandable member provide fluid communication between the lumen of the stent and the exterior of the stent.
10. A method for repairing the inner linings of damaged or diseased vertebrate vessels, said method comprising the steps of:
inserting a catheter into a vessel, wherein said catheter has a graft construct comprising submucosal tissue of a warm blooded vertebrate removably fixed to its distal end;
positioning the graft construct at a site within the vessel in need of repair;
biasing the graft construct against the luminal surface of the vessel to fix the graft construct to the luminal surface; and
removing the catheter.
11. The method of claim 10 wherein the catheter is a balloon-expandable catheter and the step of biasing the graft construct comprises inflating the balloon.
12. The method of claim 10 wherein graft construct further comprises a stent, and the submucosal tissue covers at least a portion of the exterior surface of the stent.
13. The method of claim 10 wherein the vessel is a blood vessel.
14. An improved vascular stent for expanding obstructed vessels, said stent formed as an expandable tube having an exterior and luminal surface, the improvement comprising fixing a layer of submucosal tissue to the external surface of the stent.
15. The improved vascular stent of claim 14 further comprising a layer of submucosal tissue covering the luminal surface of the stent.
16. The improved vascular stent of claim 14 wherein a strip of submucosal tissue is wrapped longitudinally about the luminal and exterior surfaces of the stent a plurality of times to form loops of submucosal tissue and wherein each loop of submucosal tissue partially overlaps an adjacent loop of submucosal tissue.
17. The improved vascular stent of claim 14 wherein the layer of submucosal tissue is formed as a tube of submucosal tissue, wherein the tube is provided with a plurality of longitudinal slits.
18. The improved vascular stent of claim 17 wherein the longitudinal slits are approximately uniform in shape and are located equidistant from one another.
19. The device of claim 14, wherein the layer of submucosal tissue comprises a pluraltiy of narrow sheets of submucosal tissue having a first end and a second opposite end wrapped longitudinally about the luminal and exterior surface of the stent, wherein the first and second opposite ends of each sheet of submucosal tissue are bonded together to form loops of submucosal tissue and wherein each loop of submucosal tissue overlaps with another loop of submucosal tissue.
20. The improved vascular stent of claim 14 wherein the stent comprises a wire that is coiled and shaped in the form of an incomplete tube, and the submucosal tissue is fixed to the stent by braiding a plurality of narrow sheets of submucosal tissue around the wire forming the stent.
US10/287,416 1994-04-29 2002-11-04 Reduction of stent thrombogenicity Abandoned US20030065379A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/287,416 US20030065379A1 (en) 1994-04-29 2002-11-04 Reduction of stent thrombogenicity

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US23530094A 1994-04-29 1994-04-29
US35022394A 1994-12-06 1994-12-06
US08/429,308 US5693085A (en) 1994-04-29 1995-04-26 Stent with collagen
US3268296P 1996-12-10 1996-12-10
US09/319,718 US6475232B1 (en) 1996-12-10 1997-12-10 Stent with reduced thrombogenicity
US10/287,416 US20030065379A1 (en) 1994-04-29 2002-11-04 Reduction of stent thrombogenicity

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/US1997/022586 Continuation WO1998025544A1 (en) 1996-12-10 1997-12-10 Stent with reduced thrombogenicity
US09/319,718 Continuation US6475232B1 (en) 1994-04-29 1997-12-10 Stent with reduced thrombogenicity

Publications (1)

Publication Number Publication Date
US20030065379A1 true US20030065379A1 (en) 2003-04-03

Family

ID=26708749

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/319,718 Expired - Lifetime US6475232B1 (en) 1994-04-29 1997-12-10 Stent with reduced thrombogenicity
US10/287,416 Abandoned US20030065379A1 (en) 1994-04-29 2002-11-04 Reduction of stent thrombogenicity

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/319,718 Expired - Lifetime US6475232B1 (en) 1994-04-29 1997-12-10 Stent with reduced thrombogenicity

Country Status (1)

Country Link
US (2) US6475232B1 (en)

Cited By (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144694A1 (en) * 2002-01-14 2003-07-31 Nmt Medical, Inc. Patent foramen ovale (PFO) closure method and device
US20030225421A1 (en) * 2002-03-25 2003-12-04 Nmt Medical, Inc. Patent foramen ovale (PFO) closure clips
US20040073242A1 (en) * 2002-06-05 2004-04-15 Nmt Medical, Inc. Patent foramen ovale (PFO) closure device with radial and circumferential support
US20040093017A1 (en) * 2002-11-06 2004-05-13 Nmt Medical, Inc. Medical devices utilizing modified shape memory alloy
US20040098121A1 (en) * 2002-11-07 2004-05-20 Nmt Medical, Inc. Patent foramen ovale (PFO) closure with magnetic force
US20040098042A1 (en) * 2002-06-03 2004-05-20 Devellian Carol A. Device with biological tissue scaffold for percutaneous closure of an intracardiac defect and methods thereof
US20040133236A1 (en) * 2001-12-19 2004-07-08 Nmt Medical, Inc. PFO closure device with flexible thrombogenic joint and improved dislodgement resistance
US20040176799A1 (en) * 2002-12-09 2004-09-09 Nmt Medical, Inc. Septal closure devices
US20050085898A1 (en) * 2003-10-21 2005-04-21 Cook Incorporated. Natural tissue stent
WO2005077433A1 (en) * 2004-02-09 2005-08-25 Cook Biotech Incorporated Stent graft devices having collagen coating
WO2005077432A2 (en) * 2004-02-09 2005-08-25 Cook Incorporated Cast bioremodelable graft
US20050192626A1 (en) * 2004-01-30 2005-09-01 Nmt Medical, Inc. Devices, systems, and methods for closure of cardiac openings
US20050234509A1 (en) * 2004-03-30 2005-10-20 Mmt Medical, Inc. Center joints for PFO occluders
EP1588676A1 (en) * 2003-04-22 2005-10-26 Medtronic Vascular, Inc. Stent-graft assembly with elution openings
US20050251154A1 (en) * 2004-05-06 2005-11-10 Nmt Medical, Inc. Double coil occluder
US20050267525A1 (en) * 2004-04-26 2005-12-01 Nmt Medical, Inc. Heart-shaped PFO closure device
US20050267523A1 (en) * 2004-03-03 2005-12-01 Nmt Medical Inc. Delivery/recovery system for septal occluder
US20050267524A1 (en) * 2004-04-09 2005-12-01 Nmt Medical, Inc. Split ends closure device
US20050273135A1 (en) * 2004-05-07 2005-12-08 Nmt Medical, Inc. Catching mechanisms for tubular septal occluder
US20050288786A1 (en) * 2004-05-07 2005-12-29 Nmt Medical, Inc. Closure device with hinges
EP1643944A2 (en) * 2003-06-17 2006-04-12 C.R. Bard, Inc. Expandable tissue support member and method of forming the support member
US20060136027A1 (en) * 2004-12-20 2006-06-22 Randy Westlund Lead electrode incorporating extracellular matrix
US20060134079A1 (en) * 2004-12-20 2006-06-22 Sih Haris J Implantable medical devices comprising isolated extracellular matrix
US20060217761A1 (en) * 2005-03-24 2006-09-28 Opolski Steven W Curved arm intracardiac occluder
US20060217760A1 (en) * 2005-03-17 2006-09-28 Widomski David R Multi-strand septal occluder
US20060241687A1 (en) * 2005-03-16 2006-10-26 Glaser Erik N Septal occluder with pivot arms and articulating joints
US20070027535A1 (en) * 2005-07-28 2007-02-01 Cook Incorporated Implantable thromboresistant valve
US20070162103A1 (en) * 2001-02-05 2007-07-12 Cook Incorporated Implantable device with remodelable material and covering material
US20070167981A1 (en) * 2005-12-22 2007-07-19 Nmt Medical, Inc. Catch members for occluder devices
US20070244517A1 (en) * 2006-03-31 2007-10-18 Nmt Medical, Inc. Deformable flap catch mechanism for occluder device
US20070276415A1 (en) * 2006-03-31 2007-11-29 Nmt Medical, Inc. Screw catch mechanism for PFO occluder and method of use
US20080249562A1 (en) * 2007-04-05 2008-10-09 Nmt Medical, Inc. Septal closure device with centering mechanism
US20090238855A1 (en) * 2007-05-10 2009-09-24 Matheny Robert G Laminate sheet articles for tissue regeneration
US7658747B2 (en) 2003-03-12 2010-02-09 Nmt Medical, Inc. Medical device for manipulation of a medical implant
US7678123B2 (en) 2003-07-14 2010-03-16 Nmt Medical, Inc. Tubular patent foramen ovale (PFO) closure device with catch system
US7764995B2 (en) 2004-06-07 2010-07-27 Cardiac Pacemakers, Inc. Method and apparatus to modulate cellular regeneration post myocardial infarct
US7766820B2 (en) 2002-10-25 2010-08-03 Nmt Medical, Inc. Expandable sheath tubing
US7840263B2 (en) 2004-02-27 2010-11-23 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression
US7867250B2 (en) 2001-12-19 2011-01-11 Nmt Medical, Inc. Septal occluder and associated methods
US7963952B2 (en) 2003-08-19 2011-06-21 Wright Jr John A Expandable sheath tubing
US8060219B2 (en) 2004-12-20 2011-11-15 Cardiac Pacemakers, Inc. Epicardial patch including isolated extracellular matrix with pacing electrodes
US8277480B2 (en) 2005-03-18 2012-10-02 W.L. Gore & Associates, Inc. Catch member for PFO occluder
US8308760B2 (en) 2004-05-06 2012-11-13 W.L. Gore & Associates, Inc. Delivery systems and methods for PFO closure device with two anchors
US8480706B2 (en) 2003-07-14 2013-07-09 W.L. Gore & Associates, Inc. Tubular patent foramen ovale (PFO) closure device with catch system
US8753362B2 (en) 2003-12-09 2014-06-17 W.L. Gore & Associates, Inc. Double spiral patent foramen ovale closure clamp
US8764848B2 (en) 2004-09-24 2014-07-01 W.L. Gore & Associates, Inc. Occluder device double securement system for delivery/recovery of such occluder device
US8870913B2 (en) 2006-03-31 2014-10-28 W.L. Gore & Associates, Inc. Catch system with locking cap for patent foramen ovale (PFO) occluder
US9138562B2 (en) 2007-04-18 2015-09-22 W.L. Gore & Associates, Inc. Flexible catheter system
US9192463B2 (en) 2010-08-03 2015-11-24 Cook Medical Technologies, LLC Blood perfusion device
US9474517B2 (en) 2008-03-07 2016-10-25 W. L. Gore & Associates, Inc. Heart occlusion devices
US9770232B2 (en) 2011-08-12 2017-09-26 W. L. Gore & Associates, Inc. Heart occlusion devices
US9808230B2 (en) 2014-06-06 2017-11-07 W. L. Gore & Associates, Inc. Sealing device and delivery system
US9861346B2 (en) 2003-07-14 2018-01-09 W. L. Gore & Associates, Inc. Patent foramen ovale (PFO) closure device with linearly elongating petals
US10271970B2 (en) 2010-08-03 2019-04-30 Cook Medical Technologies Llc Blood perfusion device
US10792025B2 (en) 2009-06-22 2020-10-06 W. L. Gore & Associates, Inc. Sealing device and delivery system
US10806437B2 (en) 2009-06-22 2020-10-20 W. L. Gore & Associates, Inc. Sealing device and delivery system
US10828019B2 (en) 2013-01-18 2020-11-10 W.L. Gore & Associates, Inc. Sealing device and delivery system

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6485723B1 (en) * 1995-02-10 2002-11-26 Purdue Research Foundation Enhanced submucosal tissue graft constructs
ES2208974T3 (en) 1996-08-23 2004-06-16 Cook Biotech, Inc. PROTESIS OF GRAFT, MATERIALS AND METHODS.
US6666892B2 (en) * 1996-08-23 2003-12-23 Cook Biotech Incorporated Multi-formed collagenous biomaterial medical device
US8716227B2 (en) * 1996-08-23 2014-05-06 Cook Biotech Incorporated Graft prosthesis, materials and methods
DE69928224T2 (en) * 1998-01-26 2006-08-03 Anson Medical Ltd., Didcot REINFORCED IMPLANT
US20050154446A1 (en) * 1998-01-26 2005-07-14 Peter Phillips Reinforced graft
US7520890B2 (en) 1998-01-26 2009-04-21 Phillips Peter W Reinforced graft and method of deployment
JP4399585B2 (en) * 1998-06-02 2010-01-20 クック インコーポレイティド Multi-sided medical device
US8882850B2 (en) 1998-12-01 2014-11-11 Cook Biotech Incorporated Multi-formed collagenous biomaterial medical device
EP1051116B8 (en) * 1998-12-01 2009-06-10 Washington University Embolization device
CA2319443C (en) * 1998-12-01 2009-09-29 Cook Biotech, Inc. Collagenous biomaterials formed with submucosal tissue
US8382821B2 (en) * 1998-12-03 2013-02-26 Medinol Ltd. Helical hybrid stent
DE60041703D1 (en) * 1999-08-06 2009-04-16 Cook Biotech Inc TUBULAR TRANSPLANT CONSTRUCTION
US10172730B2 (en) 1999-11-19 2019-01-08 Vactronix Scientific, Llc Stents with metallic covers and methods of making same
US6537310B1 (en) 1999-11-19 2003-03-25 Advanced Bio Prosthetic Surfaces, Ltd. Endoluminal implantable devices and method of making same
US7736687B2 (en) 2006-01-31 2010-06-15 Advance Bio Prosthetic Surfaces, Ltd. Methods of making medical devices
CA2397746C (en) * 2000-02-03 2010-07-27 Cook Incorporated Implantable vascular device
DE60136925D1 (en) * 2000-05-04 2009-01-22 Univ Oregon Health & Science ENDOVASCULAR STENT POWER
US20040088037A1 (en) * 2000-12-27 2004-05-06 American Medical Systems, Inc. Method and apparatus for making a braided stent with spherically ended wires
US7993365B2 (en) * 2001-06-08 2011-08-09 Morris Innovative, Inc. Method and apparatus for sealing access
US20060004408A1 (en) * 2001-06-08 2006-01-05 Morris Edward J Method and apparatus for sealing access
AU2002320189B2 (en) * 2001-06-28 2007-04-26 Cook Biotech Incorporated Graft prosthesis devices containing renal capsule collagen
US6579307B2 (en) * 2001-07-19 2003-06-17 The Cleveland Clinic Foundation Endovascular prosthesis having a layer of biological tissue
US7377938B2 (en) 2001-07-19 2008-05-27 The Cleveland Clinic Foundation Prosthetic cardiac value and method for making same
US6893431B2 (en) * 2001-10-15 2005-05-17 Scimed Life Systems, Inc. Medical device for delivering patches
DE60225824T2 (en) * 2001-10-26 2009-04-16 Cook Biotech, Inc., West Lafayette MEDICAL IMPLANT WITH NETWORK STRUCTURE
US6918926B2 (en) * 2002-04-25 2005-07-19 Medtronic Vascular, Inc. System for transrenal/intraostial fixation of endovascular prosthesis
CN1713861A (en) 2002-05-02 2005-12-28 普渡研究基金会 Vascularization enhanced graft constructs
CN1684589A (en) * 2002-05-02 2005-10-19 普渡研究基金会 Vascularization enhanced graft constructs
EP1585426A4 (en) * 2002-05-02 2006-09-20 Cook Biotech Inc Cell-seeded extracellular matrix grafts
NZ536564A (en) * 2002-05-02 2008-05-30 Purdue Research Foundation Vascularization enhanced graft constructs which comprise a matrix composition consisting of liver basement membrane
IL149828A (en) * 2002-05-23 2007-09-20 Ronnie Levi Medical device having a tubular portion
US7682392B2 (en) 2002-10-30 2010-03-23 Depuy Spine, Inc. Regenerative implants for stabilizing the spine and devices for attachment of said implants
US7992566B2 (en) 2002-12-30 2011-08-09 Quiescence Medical, Inc. Apparatus and methods for treating sleep apnea
US7647931B2 (en) * 2002-12-30 2010-01-19 Quiescence Medical, Inc. Stent for maintaining patency of a body region
US7318836B2 (en) 2003-03-11 2008-01-15 Boston Scientific Scimed, Inc. Covered stent
US7702399B2 (en) 2003-04-11 2010-04-20 Cardiac Pacemakers, Inc. Subcutaneous electrode and lead with phoresis based pharmacological agent delivery
US7529592B2 (en) * 2003-04-11 2009-05-05 Cardiac Pacemakers, Inc. Subcutaneous electrode and lead with temporary pharmacological agents
BRPI0410324A (en) 2003-05-15 2006-05-23 Biomerix Corp implantable device, elastomeric matrix production lyophilization processes having a cross-linked structure, polymerization for cross-linked elastomeric matrix preparation and cross-linked composite elastomeric implant preparation, and method for treating an orthopedic disorder
US7105001B2 (en) * 2003-05-21 2006-09-12 Mandelbaum Jon A Surgical method and composition utilizing submucosal tissue to prevent incisional hernias
US7645229B2 (en) * 2003-09-26 2010-01-12 Armstrong David N Instrument and method for endoscopic visualization and treatment of anorectal fistula
US7763077B2 (en) 2003-12-24 2010-07-27 Biomerix Corporation Repair of spinal annular defects and annulo-nucleoplasty regeneration
CN1909840B (en) * 2004-01-21 2012-03-21 库克公司 Implantable graft to close a fistula
WO2005079675A2 (en) * 2004-02-17 2005-09-01 Cook Biotech Incorporated Medical devices and methods for applying bolster material
CA2560876A1 (en) * 2004-03-29 2005-10-13 Cook Biotech Incorporated Medical graft products with differing regions and methods and systems for producing the same
WO2005117757A2 (en) * 2004-05-27 2005-12-15 St. John Health Capsulated stent and its uses
US7442206B2 (en) * 2004-10-28 2008-10-28 Cook Incorporated Methods and systems for modifying vascular valves
EP1827527B1 (en) * 2004-12-06 2016-08-24 Cook Incorporated Inflatable occlusion devices, methods, and systems
WO2006074060A2 (en) * 2004-12-30 2006-07-13 Cook Incorporated Inverting occlusion devices and systems
US20060206139A1 (en) * 2005-01-19 2006-09-14 Tekulve Kurt J Vascular occlusion device
US9138445B2 (en) * 2005-03-09 2015-09-22 Cook Biotech Incorporated Medical graft materials with adherent extracellular matrix fibrous mass
DE102005016103B4 (en) * 2005-04-08 2014-10-09 Merit Medical Systems, Inc. Duodenumstent
DE102005019649A1 (en) * 2005-04-26 2006-11-02 Alveolus Inc. Flexible stent for positioning in lumen of esophagus comprises tube and stabilization members defined circumferentially about tube, where each member extends inwardly in tube to define inner diameter that is less than inner diameter of tube
US20060251702A1 (en) * 2005-05-05 2006-11-09 Cook Biotech Incorporated Implantable materials and methods for inhibiting tissue adhesion formation
JP2008543504A (en) 2005-06-21 2008-12-04 クック・インコーポレイテッド Implantable graft to close the fistula
US7850985B2 (en) * 2005-07-05 2010-12-14 Cook Biotech Incorporated Tissue augmentation devices and methods
US9271817B2 (en) 2005-07-05 2016-03-01 Cook Biotech Incorporated Tissue augmentation devices and methods
US8771340B2 (en) * 2005-08-25 2014-07-08 Cook Medical Technologies Llc Methods and devices for the endoluminal deployment and securement of prostheses
US8470022B2 (en) * 2005-08-31 2013-06-25 Cook Biotech Incorporated Implantable valve
WO2007028052A2 (en) * 2005-09-01 2007-03-08 Cook Incorporated Attachment of material to an implantable frame by cross-linking
WO2007064819A2 (en) * 2005-12-02 2007-06-07 Cook Incorporated Devices, systems, and methods for occluding a defect
US7815923B2 (en) 2005-12-29 2010-10-19 Cook Biotech Incorporated Implantable graft material
US9155641B2 (en) * 2006-03-09 2015-10-13 Cook Medical Technologies Llc Expandable stent grafts
AU2007260914B2 (en) * 2006-06-21 2012-11-29 Cook Biotech Incorporated Fistula grafts and related methods and systems useful for treating gastrointestinal fistulae
EP2037850A2 (en) 2006-07-06 2009-03-25 Quiescence Medical Inc Apparatus and methods for treating sleep apnea
EP2053975A1 (en) * 2006-08-24 2009-05-06 Wilson-Cook Medical Inc. Devices and methods for occluding a fistula
CA2667214C (en) * 2006-10-23 2015-12-01 Cook Biotech Incorporated Processed ecm materials with enhanced component profiles
US8795384B2 (en) * 2007-01-10 2014-08-05 Cook Biotech Incorporated Implantable devices useful for reinforcing a surgically created stoma
WO2008134610A1 (en) 2007-04-27 2008-11-06 Cook Biotech Incorporated Growth factor modified extracellular matrix material and methods for preparation and use thereof
US20090112238A1 (en) * 2007-10-26 2009-04-30 Vance Products Inc., D/B/A Cook Urological Inc. Fistula brush device
JP5214223B2 (en) * 2007-11-15 2013-06-19 船井電機株式会社 projector
US8679176B2 (en) 2007-12-18 2014-03-25 Cormatrix Cardiovascular, Inc Prosthetic tissue valve
US8257434B2 (en) 2007-12-18 2012-09-04 Cormatrix Cardiovascular, Inc. Prosthetic tissue valve
WO2009102439A1 (en) * 2008-02-11 2009-08-20 William Cook Europe Aps Prosthesis coupling device and method
EP2259809B1 (en) 2008-02-29 2016-05-25 Cook Biotech Incorporated Coated embolization device
US8118832B1 (en) 2008-06-16 2012-02-21 Morris Innovative, Inc. Method and apparatus for sealing access
CA2728553C (en) * 2008-07-01 2016-08-16 Cook Biotech Incorporated Isolated extracellular matrix material including subserous fascia
CA2752899A1 (en) 2009-02-18 2010-08-26 Cormatrix Cardiovascular, Inc. Compositions and methods for preventing cardiac arrhythmia
WO2010101780A2 (en) * 2009-03-04 2010-09-10 Peytant Solutions, Inc. Stents modified with material comprising amnion tissue and corresponding processes
US8291908B2 (en) * 2009-07-24 2012-10-23 Ching-Yang Wu Device for positioning tracheostomy tube
EP2477558B1 (en) 2009-09-14 2016-08-10 CircuLite, Inc. Endovascular anastomotic connector device and delivery system
US8663086B2 (en) * 2009-09-28 2014-03-04 Cook Biotech Incorporated Medical reinforcement graft
US8333727B2 (en) * 2009-10-08 2012-12-18 Circulite, Inc. Two piece endovascular anastomotic connector
US9750866B2 (en) 2010-02-11 2017-09-05 Circulite, Inc. Cannula lined with tissue in-growth material
EP2533824B1 (en) 2010-02-11 2019-01-02 CircuLite, Inc. Devices for establishing supplemental blood flow in the circulatory system
WO2012082791A2 (en) 2010-12-13 2012-06-21 Quiescence Medical, Inc. Apparatus and methods for treating sleep apnea
AU2012262549B2 (en) 2011-05-27 2016-02-11 Cormatrix Cardiovascular, Inc. Extracellular matrix material valve conduit and methods of making thereof
US8915941B2 (en) 2011-06-14 2014-12-23 Cook Medical Technologies Llc Fistula closure devices and methods
WO2015042298A1 (en) * 2013-09-20 2015-03-26 Neograft Technologies, Inc. Graft devices with spines and related systems and methods
US9878071B2 (en) 2013-10-16 2018-01-30 Purdue Research Foundation Collagen compositions and methods of use
KR102624370B1 (en) 2014-03-21 2024-01-15 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 Methods for preparation of a terminally sterilized hydrogel derived from extracellular matrix
US20160045300A1 (en) * 2014-05-16 2016-02-18 Terumo Kabushiki Kaisha Method and apparatus for treating urethral stricture
US9883937B2 (en) * 2014-05-16 2018-02-06 Terumo Kabushiki Kaisha Method and apparatus for treating urethral stricture
US10076644B2 (en) 2014-05-16 2018-09-18 Terumo Kabushiki Kaisha Method and apparatus for treating urethral stricture
EP4193965A1 (en) * 2015-03-12 2023-06-14 Cedars-Sinai Medical Center Devices, systems, and methods to optimize annular orientation of transcatheter valves
US11919941B2 (en) 2015-04-21 2024-03-05 Purdue Research Foundation Cell-collagen-silica composites and methods of making and using the same
ES2931299T3 (en) 2017-03-02 2022-12-28 Univ Pittsburgh Commonwealth Sys Higher Education Extracellular matrix (ECM) hydrogel and soluble fraction thereof for use in the treatment of cancer
EP4252842A3 (en) 2017-03-02 2023-10-25 University of Pittsburgh- Of the Commonwealth System of Higher Education Ecm hydrogel for treating esophageal inflammation
CA3061428A1 (en) 2017-04-25 2018-11-01 Purdue Research Foundation 3-dimensional (3d) tissue-engineered muscle for tissue restoration
US10925757B2 (en) * 2018-03-21 2021-02-23 Medtronic Vascular, Inc. Tissue-coated articles
US11278391B2 (en) 2018-08-30 2022-03-22 Cook Medical Technologies Llc Graft having at least one woven taper
US10555802B1 (en) * 2019-03-07 2020-02-11 John H. Shadduck Urologic stents and methods of use
US11690705B2 (en) 2019-03-15 2023-07-04 Cook Medical Technologies Llc Graft having a pocket for receiving a stent and woven graft material, forming a pocket
US11826490B1 (en) 2020-12-29 2023-11-28 Acell, Inc. Extracellular matrix sheet devices with improved mechanical properties and method of making
KR102535728B1 (en) * 2021-05-18 2023-05-30 주식회사 비씨엠 Manufactured method of a covered stent and a covered stent by manufactured method thereof
EP4279027A3 (en) * 2022-04-29 2024-02-07 Cortronik GmbH Biological cover

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3562820A (en) * 1966-08-22 1971-02-16 Bernhard Braun Tubular sheet and strip form prostheses on a basis of biological tissue
US4776337A (en) * 1985-11-07 1988-10-11 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4902508A (en) * 1988-07-11 1990-02-20 Purdue Research Foundation Tissue graft composition
US4986831A (en) * 1988-04-25 1991-01-22 Angeion Corporation Medical implant
US5078736A (en) * 1990-05-04 1992-01-07 Interventional Thermodynamics, Inc. Method and apparatus for maintaining patency in the body passages
US5122154A (en) * 1990-08-15 1992-06-16 Rhodes Valentine J Endovascular bypass graft
US5123917A (en) * 1990-04-27 1992-06-23 Lee Peter Y Expandable intraluminal vascular graft
US5192307A (en) * 1987-12-08 1993-03-09 Wall W Henry Angioplasty stent
US5275826A (en) * 1992-11-13 1994-01-04 Purdue Research Foundation Fluidized intestinal submucosa and its use as an injectable tissue graft
US5281422A (en) * 1991-09-24 1994-01-25 Purdue Research Foundation Graft for promoting autogenous tissue growth
US5316023A (en) * 1992-01-08 1994-05-31 Expandable Grafts Partnership Method for bilateral intra-aortic bypass
US5554389A (en) * 1995-04-07 1996-09-10 Purdue Research Foundation Urinary bladder submucosa derived tissue graft
US5554183A (en) * 1994-01-19 1996-09-10 Nazari; Stefano Vascular prosthesis for the substitution or internal lining of blood vessels of medium or large diameter and device for its application
US5665115A (en) * 1992-02-21 1997-09-09 Boston Scientific Technology, Inc. Intraluminal stent
US5681345A (en) * 1995-03-01 1997-10-28 Scimed Life Systems, Inc. Sleeve carrying stent
US5693085A (en) * 1994-04-29 1997-12-02 Scimed Life Systems, Inc. Stent with collagen
US5782904A (en) * 1993-09-30 1998-07-21 Endogad Research Pty Limited Intraluminal graft
US5824037A (en) * 1995-10-03 1998-10-20 Medtronic, Inc. Modular intraluminal prostheses construction and methods
US6165212A (en) * 1993-10-21 2000-12-26 Corvita Corporation Expandable supportive endoluminal grafts
US6805706B2 (en) * 2002-08-15 2004-10-19 Gmp Cardiac Care, Inc. Stent-graft with rails

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2273250C (en) 1996-12-10 2008-01-29 Cook Biotech, Inc. Stent grafts containing purified submucosa
CA2267310C (en) 1996-12-10 2012-09-18 Purdue Research Foundation Stomach submucosa derived tissue graft

Patent Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3562820A (en) * 1966-08-22 1971-02-16 Bernhard Braun Tubular sheet and strip form prostheses on a basis of biological tissue
US4776337A (en) * 1985-11-07 1988-10-11 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4776337B1 (en) * 1985-11-07 2000-12-05 Cordis Corp Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5192307A (en) * 1987-12-08 1993-03-09 Wall W Henry Angioplasty stent
US4986831A (en) * 1988-04-25 1991-01-22 Angeion Corporation Medical implant
US4902508A (en) * 1988-07-11 1990-02-20 Purdue Research Foundation Tissue graft composition
US5123917A (en) * 1990-04-27 1992-06-23 Lee Peter Y Expandable intraluminal vascular graft
US5078736A (en) * 1990-05-04 1992-01-07 Interventional Thermodynamics, Inc. Method and apparatus for maintaining patency in the body passages
US5122154A (en) * 1990-08-15 1992-06-16 Rhodes Valentine J Endovascular bypass graft
US5281422A (en) * 1991-09-24 1994-01-25 Purdue Research Foundation Graft for promoting autogenous tissue growth
US5316023A (en) * 1992-01-08 1994-05-31 Expandable Grafts Partnership Method for bilateral intra-aortic bypass
US5683453A (en) * 1992-01-08 1997-11-04 Expandable Grafts Partnership Apparatus for bilateral intra-aortic bypass
US5665115A (en) * 1992-02-21 1997-09-09 Boston Scientific Technology, Inc. Intraluminal stent
US5275826A (en) * 1992-11-13 1994-01-04 Purdue Research Foundation Fluidized intestinal submucosa and its use as an injectable tissue graft
US5782904A (en) * 1993-09-30 1998-07-21 Endogad Research Pty Limited Intraluminal graft
US6565596B1 (en) * 1993-09-30 2003-05-20 Endogad Research Pty Limited Intraluminal graft
US6165212A (en) * 1993-10-21 2000-12-26 Corvita Corporation Expandable supportive endoluminal grafts
US5554183A (en) * 1994-01-19 1996-09-10 Nazari; Stefano Vascular prosthesis for the substitution or internal lining of blood vessels of medium or large diameter and device for its application
US5693085A (en) * 1994-04-29 1997-12-02 Scimed Life Systems, Inc. Stent with collagen
US5681345A (en) * 1995-03-01 1997-10-28 Scimed Life Systems, Inc. Sleeve carrying stent
US5554389A (en) * 1995-04-07 1996-09-10 Purdue Research Foundation Urinary bladder submucosa derived tissue graft
US5824037A (en) * 1995-10-03 1998-10-20 Medtronic, Inc. Modular intraluminal prostheses construction and methods
US6805706B2 (en) * 2002-08-15 2004-10-19 Gmp Cardiac Care, Inc. Stent-graft with rails

Cited By (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070162103A1 (en) * 2001-02-05 2007-07-12 Cook Incorporated Implantable device with remodelable material and covering material
US8038708B2 (en) 2001-02-05 2011-10-18 Cook Medical Technologies Llc Implantable device with remodelable material and covering material
US20080228218A1 (en) * 2001-12-19 2008-09-18 Nmt Medical, Inc. Pfo closure device with flexible thrombogenic joint and improved dislodgement resistance
US7867250B2 (en) 2001-12-19 2011-01-11 Nmt Medical, Inc. Septal occluder and associated methods
US20040133236A1 (en) * 2001-12-19 2004-07-08 Nmt Medical, Inc. PFO closure device with flexible thrombogenic joint and improved dislodgement resistance
US7967840B2 (en) 2001-12-19 2011-06-28 Nmt Medical, Inc. PFO closure device with flexible thrombogenic joint and improved dislodgement resistance
US8758403B2 (en) 2001-12-19 2014-06-24 W.L. Gore & Associates, Inc. PFO closure device with flexible thrombogenic joint and improved dislodgement resistance
US20030144694A1 (en) * 2002-01-14 2003-07-31 Nmt Medical, Inc. Patent foramen ovale (PFO) closure method and device
US20030225421A1 (en) * 2002-03-25 2003-12-04 Nmt Medical, Inc. Patent foramen ovale (PFO) closure clips
US9241695B2 (en) 2002-03-25 2016-01-26 W.L. Gore & Associates, Inc. Patent foramen ovale (PFO) closure clips
US20070198060A1 (en) * 2002-06-03 2007-08-23 Nmt Medical, Inc. Device with biological tissue scaffold for percutaneous closure of an intracardiac defect and methods thereof
US20040098042A1 (en) * 2002-06-03 2004-05-20 Devellian Carol A. Device with biological tissue scaffold for percutaneous closure of an intracardiac defect and methods thereof
US9216014B2 (en) 2002-06-03 2015-12-22 W.L. Gore & Associates, Inc. Device with biological tissue scaffold for percutaneous closure of an intracardiac defect and methods thereof
US9028527B2 (en) 2002-06-05 2015-05-12 W.L. Gore & Associates, Inc. Patent foramen ovale (PFO) closure device with radial and circumferential support
US20040073242A1 (en) * 2002-06-05 2004-04-15 Nmt Medical, Inc. Patent foramen ovale (PFO) closure device with radial and circumferential support
US8784448B2 (en) 2002-06-05 2014-07-22 W.L. Gore & Associates, Inc. Patent foramen ovale (PFO) closure device with radial and circumferential support
US7766820B2 (en) 2002-10-25 2010-08-03 Nmt Medical, Inc. Expandable sheath tubing
US20040093017A1 (en) * 2002-11-06 2004-05-13 Nmt Medical, Inc. Medical devices utilizing modified shape memory alloy
US20040098121A1 (en) * 2002-11-07 2004-05-20 Nmt Medical, Inc. Patent foramen ovale (PFO) closure with magnetic force
US20040176799A1 (en) * 2002-12-09 2004-09-09 Nmt Medical, Inc. Septal closure devices
US9017373B2 (en) 2002-12-09 2015-04-28 W.L. Gore & Associates, Inc. Septal closure devices
US7658747B2 (en) 2003-03-12 2010-02-09 Nmt Medical, Inc. Medical device for manipulation of a medical implant
EP1588676A1 (en) * 2003-04-22 2005-10-26 Medtronic Vascular, Inc. Stent-graft assembly with elution openings
EP1643944A4 (en) * 2003-06-17 2011-04-20 Bard Inc C R Expandable tissue support member and method of forming the support member
EP1643944A2 (en) * 2003-06-17 2006-04-12 C.R. Bard, Inc. Expandable tissue support member and method of forming the support member
US9861346B2 (en) 2003-07-14 2018-01-09 W. L. Gore & Associates, Inc. Patent foramen ovale (PFO) closure device with linearly elongating petals
US11375988B2 (en) 2003-07-14 2022-07-05 W. L. Gore & Associates, Inc. Patent foramen ovale (PFO) closure device with linearly elongating petals
US9149263B2 (en) 2003-07-14 2015-10-06 W. L. Gore & Associates, Inc. Tubular patent foramen ovale (PFO) closure device with catch system
US8480706B2 (en) 2003-07-14 2013-07-09 W.L. Gore & Associates, Inc. Tubular patent foramen ovale (PFO) closure device with catch system
US9326759B2 (en) 2003-07-14 2016-05-03 W.L. Gore & Associates, Inc. Tubular patent foramen ovale (PFO) closure device with catch system
US7678123B2 (en) 2003-07-14 2010-03-16 Nmt Medical, Inc. Tubular patent foramen ovale (PFO) closure device with catch system
US7963952B2 (en) 2003-08-19 2011-06-21 Wright Jr John A Expandable sheath tubing
US7056337B2 (en) 2003-10-21 2006-06-06 Cook Incorporated Natural tissue stent
US20050085898A1 (en) * 2003-10-21 2005-04-21 Cook Incorporated. Natural tissue stent
WO2005042050A1 (en) * 2003-10-21 2005-05-12 Cook Incorporated Natural tissue stent
US8753362B2 (en) 2003-12-09 2014-06-17 W.L. Gore & Associates, Inc. Double spiral patent foramen ovale closure clamp
US20050192626A1 (en) * 2004-01-30 2005-09-01 Nmt Medical, Inc. Devices, systems, and methods for closure of cardiac openings
US20050209636A1 (en) * 2004-01-30 2005-09-22 Nmt Medical, Inc. Devices, systems, and methods for closure of cardiac openings
US20050216054A1 (en) * 2004-01-30 2005-09-29 Nmt Medical, Inc. Devices, systems and methods for closure of cardiac openings
US8361111B2 (en) 2004-01-30 2013-01-29 W.L. Gore & Associates, Inc. Devices, systems and methods for closure of cardiac openings
US8262694B2 (en) 2004-01-30 2012-09-11 W.L. Gore & Associates, Inc. Devices, systems, and methods for closure of cardiac openings
WO2005077433A1 (en) * 2004-02-09 2005-08-25 Cook Biotech Incorporated Stent graft devices having collagen coating
WO2005077432A3 (en) * 2004-02-09 2006-03-30 Cook Inc Cast bioremodelable graft
AU2005212335B2 (en) * 2004-02-09 2010-01-28 Cook Biotech, Inc. Cast bioremodelable graft
US20070112411A1 (en) * 2004-02-09 2007-05-17 Obermiller F J Stent graft devices having collagen coating
GB2430626B (en) * 2004-02-09 2008-09-24 Cook Biotech Inc Stent graft devices having collagen coating
US10420636B2 (en) * 2004-02-09 2019-09-24 Cook Medical Technologies Llc Stent graft devices having collagen coating
GB2430626A (en) * 2004-02-09 2007-04-04 Cook Biotech Inc Stent graft devices having collagen coating
WO2005077432A2 (en) * 2004-02-09 2005-08-25 Cook Incorporated Cast bioremodelable graft
US7840263B2 (en) 2004-02-27 2010-11-23 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression
US7871419B2 (en) 2004-03-03 2011-01-18 Nmt Medical, Inc. Delivery/recovery system for septal occluder
US8568431B2 (en) 2004-03-03 2013-10-29 W.L. Gore & Associates, Inc. Delivery/recovery system for septal occluder
US20050267523A1 (en) * 2004-03-03 2005-12-01 Nmt Medical Inc. Delivery/recovery system for septal occluder
US8945158B2 (en) 2004-03-03 2015-02-03 W.L. Gore & Associates, Inc. Delivery/recovery system for septal occluder
US20110112633A1 (en) * 2004-03-03 2011-05-12 Nmt Medical, Inc. Delivery/recovery system for septal occluder
US20050234509A1 (en) * 2004-03-30 2005-10-20 Mmt Medical, Inc. Center joints for PFO occluders
US8828049B2 (en) 2004-04-09 2014-09-09 W.L. Gore & Associates, Inc. Split ends closure device and methods of use
US20050267524A1 (en) * 2004-04-09 2005-12-01 Nmt Medical, Inc. Split ends closure device
US20050267525A1 (en) * 2004-04-26 2005-12-01 Nmt Medical, Inc. Heart-shaped PFO closure device
US8361110B2 (en) 2004-04-26 2013-01-29 W.L. Gore & Associates, Inc. Heart-shaped PFO closure device
US7842053B2 (en) 2004-05-06 2010-11-30 Nmt Medical, Inc. Double coil occluder
US20050251154A1 (en) * 2004-05-06 2005-11-10 Nmt Medical, Inc. Double coil occluder
US8568447B2 (en) 2004-05-06 2013-10-29 W.L. Gore & Associates, Inc. Delivery systems and methods for PFO closure device with two anchors
US8308760B2 (en) 2004-05-06 2012-11-13 W.L. Gore & Associates, Inc. Delivery systems and methods for PFO closure device with two anchors
US7704268B2 (en) 2004-05-07 2010-04-27 Nmt Medical, Inc. Closure device with hinges
US9545247B2 (en) 2004-05-07 2017-01-17 W.L. Gore & Associates, Inc. Catching mechanisms for tubular septal occluder
US20050288786A1 (en) * 2004-05-07 2005-12-29 Nmt Medical, Inc. Closure device with hinges
US8480709B2 (en) 2004-05-07 2013-07-09 W.L. Gore & Associates, Inc. Catching mechanisms for tubular septal occluder
US20050273135A1 (en) * 2004-05-07 2005-12-08 Nmt Medical, Inc. Catching mechanisms for tubular septal occluder
US8257389B2 (en) 2004-05-07 2012-09-04 W.L. Gore & Associates, Inc. Catching mechanisms for tubular septal occluder
US7764995B2 (en) 2004-06-07 2010-07-27 Cardiac Pacemakers, Inc. Method and apparatus to modulate cellular regeneration post myocardial infarct
US8764848B2 (en) 2004-09-24 2014-07-01 W.L. Gore & Associates, Inc. Occluder device double securement system for delivery/recovery of such occluder device
US7981065B2 (en) 2004-12-20 2011-07-19 Cardiac Pacemakers, Inc. Lead electrode incorporating extracellular matrix
US20060136027A1 (en) * 2004-12-20 2006-06-22 Randy Westlund Lead electrode incorporating extracellular matrix
US20060134079A1 (en) * 2004-12-20 2006-06-22 Sih Haris J Implantable medical devices comprising isolated extracellular matrix
US8060219B2 (en) 2004-12-20 2011-11-15 Cardiac Pacemakers, Inc. Epicardial patch including isolated extracellular matrix with pacing electrodes
US8874204B2 (en) 2004-12-20 2014-10-28 Cardiac Pacemakers, Inc. Implantable medical devices comprising isolated extracellular matrix
US20060241687A1 (en) * 2005-03-16 2006-10-26 Glaser Erik N Septal occluder with pivot arms and articulating joints
US20060217760A1 (en) * 2005-03-17 2006-09-28 Widomski David R Multi-strand septal occluder
US8636765B2 (en) 2005-03-18 2014-01-28 W.L. Gore & Associates, Inc. Catch member for PFO occluder
US8277480B2 (en) 2005-03-18 2012-10-02 W.L. Gore & Associates, Inc. Catch member for PFO occluder
US8430907B2 (en) 2005-03-18 2013-04-30 W.L. Gore & Associates, Inc. Catch member for PFO occluder
US8372113B2 (en) 2005-03-24 2013-02-12 W.L. Gore & Associates, Inc. Curved arm intracardiac occluder
US20060217761A1 (en) * 2005-03-24 2006-09-28 Opolski Steven W Curved arm intracardiac occluder
US20070027535A1 (en) * 2005-07-28 2007-02-01 Cook Incorporated Implantable thromboresistant valve
US20070167981A1 (en) * 2005-12-22 2007-07-19 Nmt Medical, Inc. Catch members for occluder devices
US9084603B2 (en) 2005-12-22 2015-07-21 W.L. Gore & Associates, Inc. Catch members for occluder devices
US20070244517A1 (en) * 2006-03-31 2007-10-18 Nmt Medical, Inc. Deformable flap catch mechanism for occluder device
US8870913B2 (en) 2006-03-31 2014-10-28 W.L. Gore & Associates, Inc. Catch system with locking cap for patent foramen ovale (PFO) occluder
US8551135B2 (en) 2006-03-31 2013-10-08 W.L. Gore & Associates, Inc. Screw catch mechanism for PFO occluder and method of use
US8814947B2 (en) 2006-03-31 2014-08-26 W.L. Gore & Associates, Inc. Deformable flap catch mechanism for occluder device
US20070276415A1 (en) * 2006-03-31 2007-11-29 Nmt Medical, Inc. Screw catch mechanism for PFO occluder and method of use
US9949728B2 (en) 2007-04-05 2018-04-24 W.L. Gore & Associates, Inc. Septal closure device with centering mechanism
US10485525B2 (en) 2007-04-05 2019-11-26 W.L. Gore & Associates, Inc. Septal closure device with centering mechanism
US20080249562A1 (en) * 2007-04-05 2008-10-09 Nmt Medical, Inc. Septal closure device with centering mechanism
US9005242B2 (en) 2007-04-05 2015-04-14 W.L. Gore & Associates, Inc. Septal closure device with centering mechanism
US9138562B2 (en) 2007-04-18 2015-09-22 W.L. Gore & Associates, Inc. Flexible catheter system
US20090238855A1 (en) * 2007-05-10 2009-09-24 Matheny Robert G Laminate sheet articles for tissue regeneration
US10278705B2 (en) 2008-03-07 2019-05-07 W. L. Gore & Associates, Inc. Heart occlusion devices
US9474517B2 (en) 2008-03-07 2016-10-25 W. L. Gore & Associates, Inc. Heart occlusion devices
US11564672B2 (en) 2009-06-22 2023-01-31 W. L. Gore & Associates, Inc. Sealing device and delivery system
US11589853B2 (en) 2009-06-22 2023-02-28 W. L. Gore & Associates, Inc. Sealing device and delivery system
US11596391B2 (en) 2009-06-22 2023-03-07 W. L. Gore & Associates, Inc. Sealing device and delivery system
US10806437B2 (en) 2009-06-22 2020-10-20 W. L. Gore & Associates, Inc. Sealing device and delivery system
US10792025B2 (en) 2009-06-22 2020-10-06 W. L. Gore & Associates, Inc. Sealing device and delivery system
US9192463B2 (en) 2010-08-03 2015-11-24 Cook Medical Technologies, LLC Blood perfusion device
US10271970B2 (en) 2010-08-03 2019-04-30 Cook Medical Technologies Llc Blood perfusion device
US9770232B2 (en) 2011-08-12 2017-09-26 W. L. Gore & Associates, Inc. Heart occlusion devices
US10828019B2 (en) 2013-01-18 2020-11-10 W.L. Gore & Associates, Inc. Sealing device and delivery system
US11771408B2 (en) 2013-01-18 2023-10-03 W. L. Gore & Associates, Inc. Sealing device and delivery system
US11298116B2 (en) 2014-06-06 2022-04-12 W. L. Gore & Associates, Inc. Sealing device and delivery system
US10368853B2 (en) 2014-06-06 2019-08-06 W. L. Gore & Associates, Inc. Sealing device and delivery system
US9808230B2 (en) 2014-06-06 2017-11-07 W. L. Gore & Associates, Inc. Sealing device and delivery system

Also Published As

Publication number Publication date
US6475232B1 (en) 2002-11-05

Similar Documents

Publication Publication Date Title
US6475232B1 (en) Stent with reduced thrombogenicity
EP1014887B1 (en) Stent with reduced thrombogenicity
WO1998025544A9 (en) Stent with reduced thrombogenicity
US8882822B2 (en) Non-thrombogenic stent jacket
US5122154A (en) Endovascular bypass graft
US5681345A (en) Sleeve carrying stent
US9907639B2 (en) Apparatus and methods for in situ embolic protection
US6117166A (en) Apparatus and methods for grafting blood vessel tissue
US6589273B1 (en) Apparatus and method for relining a blood vessel
JP2004508136A (en) Intraluminal prosthesis device having hook structure and loop structure
US20070168011A1 (en) Detachable therapeutic material
JPH09117511A (en) Combining assembly of stend and blood vessel transplant piece
JPH11511374A (en) Inflatable bifurcated support lumen implant
JP2003245359A (en) Coated segment type stent
US20100191323A1 (en) Biodegradable stent graft
van Sambeek et al. Endovascular stent-grafts for aneurysms of the femoral and popliteal arteries
WO1997012563A1 (en) Method of covering a stent with acellular matrix
EP1704835B1 (en) Stent with reduced thrombogenicity
US20070282421A1 (en) Stent Assembly for Protecting the Interior Surface of a Vessel
US7815687B2 (en) Method of promoting cell proliferation and ingrowth by injury to the native tissue
Forte et al. Endoscopic management of tracheal and esophageal strictures
RU2751811C1 (en) Method for emergency endovascular treatment of iatrogenic distal perforations of convoluted vascular bed of small diameter
Perin Autologous vein-coated stent for exclusion of a coronary artery aneurysm: case report with postimplantation intravascular ultrasound characteristics.
US7922759B1 (en) Apparatus and methods for vascular treatment
AU780149B2 (en) Non-thrombogenic stent jacket

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION